[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foJ8yJYBJ6eMZAPXqScfdcvV122hc0ldQ4iG4feObytc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":9,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":81,"rows":88},"EMD Serono",[4,6],"EMD Serono Research & Development Institute, Inc.",177,false,19,45,42177,29,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Multiple Sclerosis",18,{"name":18,"count":19},"Advanced Solid Tumor",10,{"name":21,"count":22},"Solid Tumors",8,{"name":24,"count":25},"Ovarian Cancer",6,{"name":27,"count":25},"Advanced Solid Tumors",{"name":29,"count":30},"Rheumatoid Arthritis",4,{"name":32,"count":30},"Colorectal Cancer",{"name":34,"count":30},"Relapsing-remitting Multiple Sclerosis",[36,41,45,50,55,59,64,68,72,77],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02864992","Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","2022-05-16","Tepotinib",{"nctId":42,"briefTitle":43,"date":44,"intervention":40},"NCT03940703","A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","2023-05-11",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05327530","A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","2025-06-20","Avelumab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06433219","Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)","2025-09-29","Tuvusertib",{"nctId":56,"briefTitle":57,"date":58,"intervention":49},"NCT05081180","Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors","2026-02-11",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04170153","Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","2026-07-30","M1774",{"nctId":65,"briefTitle":66,"date":67,"intervention":49},"NCT03815643","Avelumab Program Rollover Study","2026-08-21",{"nctId":69,"briefTitle":70,"date":71,"intervention":63},"NCT05882734","Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)","2026-09-30",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05464030","Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","2026-10-23","M9140",{"nctId":78,"briefTitle":79,"date":80,"intervention":54},"NCT05396833","Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)","2027-01-14",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,274,333,370,392,410,428,469,521,555,581,612,634,663,681,699,717,735,771,807,829,861,883,901,919,937,955,978,996,1021,1054,1096,1121,1139,1157,1175,1193,1211,1229,1247,1353,1422,1505,1549,1591,1645,1679,1717,1775,1810,1836,1881,1928,1960,1991,2023,2057,2092,2114,2149,2171,2193,2215,2240,2265,2283,2307,2333,2358,2383,2401,2426,2452,2470,2495,2513,2531,2549,2567,2585,2612,2630,2655,2673,2691,2717,2735,2753,2771,2795,2819,2888,2918,2956,2991,3024,3064,3086,3108,3143,3170,3188,3206,3224,3242,3271,3289,3307,3325,3343,3361,3379,3397,3415,3441,3465,3483,3508,3526,3544,3568,3586,3604,3628,3654,3672,3698,3716,3734,3752,3770,3788,3806,3831,3849,3875,3893,3919,3937,3961,3985,4003,4026,4044,4062,4080,4098,4116,4141,4159,4177,4201,4223,4249,4281,4303,4327,4345,4363,4381,4399,4417,4443,4461,4479,4504,4522,4545,4563,4581,4599,4617,4635,4653,4671,4689,4707,4725,4743,4761,4779,4797,4815,4833,4851,4869,4895,4913,4931,4954,4977,5000,5023,5046,5064,5089,5107,5133,5151,5169,5195,5213,5231,5249,5267,5285,5308,5333,5351,5369,5387,5411,5435,5459,5508,5546],{"intervention":49,"totalTrials":90,"cells":91},15,{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":171,"PHASE3":206,"PHASE4":270,"NA":272},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":170,"soonestReadout":58},[97,109,118,128,139,150,162],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT03704467","Phase Ib\u002FII Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer","COMPLETED",[83],"2019-11-06","2019-03-04",3,[24],[107,49,108],"M6620","Carboplatin",{"nctId":110,"briefTitle":111,"status":100,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT01772004","Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)",[83],"2019-12-16","2013-01-31",1756,[21],[49],{"nctId":56,"briefTitle":57,"status":119,"phases":120,"primaryCompletion":58,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"ACTIVE_NOT_RECRUITING",[83],"2026-05-29","2021-12-03",17,[125],"Central Nervous System Tumors",[49,127],"Lenvatinib",{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT02994953","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)","TERMINATED",[83],"2020-10-08","2017-01-31",52,[27],[49,138,49,138,49],"M9241",{"nctId":140,"briefTitle":141,"status":131,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":149},"NCT03451825","Phase I\u002FII Study of Avelumab in Pediatric Cancer Participants",[83],"2021-07-27","2018-03-07",21,[147,148],"Refractory or Relapsed Solid Tumors","Lymphoma",[49,49],{"nctId":151,"briefTitle":152,"status":100,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT03724890","Study of Avelumab-M3814 Combinations",[83],"2021-09-01","2022-08-17","2018-11-27",57,[159,21],"Oncology",[161,161,49],"M3814",{"nctId":78,"briefTitle":79,"status":119,"phases":163,"primaryCompletion":80,"completion":80,"start":164,"enrollment":165,"conditions":166,"interventions":168},[83],"2022-06-07",120,[167],"Metastatic or Locally Advanced Unresectable Solid Tumors",[54,169,49],"Lartesertib",2,{"trials":172,"activeCount":205,"soonestReadout":48},[173,184,194],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":94,"conditions":181,"interventions":183},"NCT06424717","Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)","WITHDRAWN",[84],"2026-01-12","2026-01-27","2024-08-16",[182],"Urothelial Carcinoma",[49,54],{"nctId":46,"briefTitle":47,"status":119,"phases":185,"primaryCompletion":48,"completion":186,"start":155,"enrollment":187,"conditions":188,"interventions":190},[84],"2026-06-25",256,[189],"Locally Advanced or Metastatic Urothelial Carcinoma",[49,191,192,193],"Sacituzumab Govitecan","M6223","NKTR-255",{"nctId":195,"briefTitle":196,"status":100,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT02155647","Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)",[84],"2019-05-02","2023-05-03","2014-07-03",204,[203],"Carcinoma, Merkel Cell",[49],1,{"trials":207,"activeCount":205,"soonestReadout":67},[208,220,226,240,255],{"nctId":209,"briefTitle":210,"status":100,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT02395172","Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)",[85],"2017-11-22","2019-12-03","2015-03-24",792,[217],"Carcinoma, Non-Small-Cell Lung",[49,219],"Docetaxel",{"nctId":65,"briefTitle":66,"status":119,"phases":221,"primaryCompletion":67,"completion":67,"start":222,"enrollment":223,"conditions":224,"interventions":225},[85],"2019-03-22",205,[21],[49],{"nctId":227,"briefTitle":228,"status":100,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":237},"NCT02625623","Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)",[85],"2017-09-14","2019-11-13","2015-12-28",371,[235,236],"Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","Gastric Cancer Third Line",[49,238,239],"Irinotecan","Paclitaxel",{"nctId":241,"briefTitle":242,"status":100,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT02576574","Avelumab in First-line NSCLC (JAVELIN Lung 100)",[85],"2021-12-06","2024-01-29","2015-10-29",1214,[249],"First Line Non-Small Cell Lung Cancer",[49,251,239,252,252,108,253,108,254],"Pemetrexed","Gemcitabine","Cisplatin","Avelumab Weekly",{"nctId":256,"briefTitle":257,"status":100,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT02625610","Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)",[85],"2019-09-13","2021-06-03","2015-12-24",499,[264],"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction",[49,266,267,268,269,266,267,268,269],"Oxaliplatin","5-Fluorouracil","Leucovorin","Capecitabine",{"trials":271,"activeCount":94},[],{"trials":273,"activeCount":94},[],{"intervention":275,"totalTrials":30,"cells":276},"Bevacizumab",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":313,"PHASE3":315,"PHASE4":329,"NA":331},{"trials":278,"activeCount":94},[],{"trials":280,"activeCount":205,"soonestReadout":75},[281,293,302],{"nctId":282,"briefTitle":283,"status":100,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT04551950","Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)",[83],"2022-06-15","2022-06-30","2020-10-19",25,[290],"Cervical Cancer",[292,108,239,275,253],"M7824",{"nctId":73,"briefTitle":74,"status":294,"phases":295,"primaryCompletion":75,"completion":75,"start":296,"enrollment":297,"conditions":298,"interventions":299},"RECRUITING",[83],"2022-08-04",200,[32],[76,76,275,269,300,301],"5-fluorouracil","Folinic acid",{"nctId":303,"briefTitle":304,"status":131,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":308,"interventions":309},"NCT06509906","M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)",[83],"2025-12-02","2024-10-08",[18],[310,238,301,311,275,312],"M9466","Fluorouracil","Granulocyte colony stimulating factor",{"trials":314,"activeCount":94},[],{"trials":316,"activeCount":205,"soonestReadout":321},[317],{"nctId":318,"briefTitle":319,"status":294,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT07549412","A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine\u002FTipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)",[85],"2029-10-16","2026-05-06",1020,[325],"Metastatic Colorectal Cancer",[327,275,328],"Precemtabart tocentecan","Trifluridine\u002FTipiracil",{"trials":330,"activeCount":94},[],{"trials":332,"activeCount":94},[],{"intervention":334,"totalTrials":170,"cells":335},"Enpatoran",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":366,"NA":368},{"trials":337,"activeCount":94},[],{"trials":339,"activeCount":94},[],{"trials":341,"activeCount":94},[],{"trials":343,"activeCount":170,"soonestReadout":360},[344,356],{"nctId":345,"briefTitle":346,"status":294,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":354},"NCT07355218","A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)",[85],"2029-05-25","2026-04-01",202,[352,353],"Systematic Lupus Erythematosus","Cutaneous Lupus Erythematosus",[334,355],"Standard of care",{"nctId":357,"briefTitle":358,"status":294,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":350,"conditions":362,"interventions":365},"NCT07332481","A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease",[85],"2029-05-24","2026-03-10",[363,364],"Systemic Lupus Erythematosus (SLE)","Cutaneous Lupus Erythematosus (CLE)",[334,355],{"trials":367,"activeCount":94},[],{"trials":369,"activeCount":94},[],{"intervention":355,"totalTrials":170,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":388,"NA":390},{"trials":373,"activeCount":94},[],{"trials":375,"activeCount":94},[],{"trials":377,"activeCount":94},[],{"trials":379,"activeCount":170,"soonestReadout":360},[380,384],{"nctId":345,"briefTitle":346,"status":294,"phases":381,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":382,"interventions":383},[85],[352,353],[334,355],{"nctId":357,"briefTitle":358,"status":294,"phases":385,"primaryCompletion":360,"completion":360,"start":361,"enrollment":350,"conditions":386,"interventions":387},[85],[363,364],[334,355],{"trials":389,"activeCount":94},[],{"trials":391,"activeCount":94},[],{"intervention":327,"totalTrials":205,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":406,"NA":408},{"trials":395,"activeCount":94},[],{"trials":397,"activeCount":94},[],{"trials":399,"activeCount":94},[],{"trials":401,"activeCount":205,"soonestReadout":321},[402],{"nctId":318,"briefTitle":319,"status":294,"phases":403,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":404,"interventions":405},[85],[325],[327,275,328],{"trials":407,"activeCount":94},[],{"trials":409,"activeCount":94},[],{"intervention":328,"totalTrials":205,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":424,"NA":426},{"trials":413,"activeCount":94},[],{"trials":415,"activeCount":94},[],{"trials":417,"activeCount":94},[],{"trials":419,"activeCount":205,"soonestReadout":321},[420],{"nctId":318,"briefTitle":319,"status":294,"phases":421,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":422,"interventions":423},[85],[325],[327,275,328],{"trials":425,"activeCount":94},[],{"trials":427,"activeCount":94},[],{"intervention":54,"totalTrials":30,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":449,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":431,"activeCount":94},[],{"trials":433,"activeCount":170,"soonestReadout":80},[434,445],{"nctId":435,"briefTitle":436,"status":119,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT06421935","M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)",[83],"2027-02-22","2024-08-07",141,[18],[310,54,443,444],"Abiraterone acetate","Prednisone\u002FPrednisolone",{"nctId":78,"briefTitle":79,"status":119,"phases":446,"primaryCompletion":80,"completion":80,"start":164,"enrollment":165,"conditions":447,"interventions":448},[83],[167],[54,169,49],{"trials":450,"activeCount":205,"soonestReadout":53},[451,455],{"nctId":174,"briefTitle":175,"status":176,"phases":452,"primaryCompletion":178,"completion":179,"start":180,"enrollment":94,"conditions":453,"interventions":454},[84],[182],[49,54],{"nctId":51,"briefTitle":52,"status":119,"phases":456,"primaryCompletion":53,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},[84],"2026-06-26","2024-10-30",63,[24],[54,462,169],"Niraparib",{"trials":464,"activeCount":94},[],{"trials":466,"activeCount":94},[],{"trials":468,"activeCount":94},[],{"intervention":40,"totalTrials":30,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":484,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":472,"activeCount":94},[],{"trials":474,"activeCount":94},[475],{"nctId":476,"briefTitle":477,"status":100,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":16,"conditions":481,"interventions":483},"NCT03546608","Tepotinib Hepatic Impairment Trial",[83],"2019-02-05","2018-06-13",[482],"Hepatic Impairment",[40],{"trials":485,"activeCount":170,"soonestReadout":39},[486,497,506],{"nctId":487,"briefTitle":488,"status":131,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":104,"conditions":493,"interventions":495},"NCT04515394","Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS\u002FBRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)",[84],"2022-03-14","2022-03-31","2021-01-28",[494],"Colorectal Neoplasms",[40,496],"Cetuximab",{"nctId":37,"briefTitle":38,"status":119,"phases":498,"primaryCompletion":39,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":505},[84],"2026-04-30","2016-09-13",337,[503,504],"Advanced (Stage IIIB\u002FIV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification","Lung Adenocarcinoma Stage IIIB\u002FIV",[40],{"nctId":42,"briefTitle":43,"status":119,"phases":507,"primaryCompletion":44,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},[84],"2026-05-01","2019-09-19",140,[512],"Non-small Cell Lung Cancer",[40,514],"Osimertinib",{"trials":516,"activeCount":94},[],{"trials":518,"activeCount":94},[],{"trials":520,"activeCount":94},[],{"intervention":462,"totalTrials":104,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":533,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":524,"activeCount":94},[],{"trials":526,"activeCount":205,"soonestReadout":62},[527],{"nctId":60,"briefTitle":61,"status":119,"phases":528,"primaryCompletion":62,"completion":62,"start":529,"enrollment":530,"conditions":531,"interventions":532},[83],"2019-12-20",161,[167],[63,462],{"trials":534,"activeCount":205,"soonestReadout":53},[535,539],{"nctId":51,"briefTitle":52,"status":119,"phases":536,"primaryCompletion":53,"completion":457,"start":458,"enrollment":459,"conditions":537,"interventions":538},[84],[24],[54,462,169],{"nctId":540,"briefTitle":541,"status":176,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":94,"conditions":545,"interventions":547},"NCT04655183","Study of M4344 in Combination With Niraparib",[83,84],"2023-09-01","2020-12-01",[18,546],"Breast Cancer",[462,548,462,548,462,462],"M4344",{"trials":550,"activeCount":94},[],{"trials":552,"activeCount":94},[],{"trials":554,"activeCount":94},[],{"intervention":63,"totalTrials":170,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":565,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":558,"activeCount":94},[],{"trials":560,"activeCount":205,"soonestReadout":62},[561],{"nctId":60,"briefTitle":61,"status":119,"phases":562,"primaryCompletion":62,"completion":62,"start":529,"enrollment":530,"conditions":563,"interventions":564},[83],[167],[63,462],{"trials":566,"activeCount":205,"soonestReadout":71},[567],{"nctId":69,"briefTitle":70,"status":119,"phases":568,"primaryCompletion":71,"completion":71,"start":569,"enrollment":570,"conditions":571,"interventions":573},[83,84],"2023-09-13",61,[572],"Non-Small Cell Lung Cancer",[63,574],"Cemiplimab",{"trials":576,"activeCount":94},[],{"trials":578,"activeCount":94},[],{"trials":580,"activeCount":94},[],{"intervention":76,"totalTrials":170,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":591,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":584,"activeCount":94},[],{"trials":586,"activeCount":205,"soonestReadout":75},[587],{"nctId":73,"briefTitle":74,"status":294,"phases":588,"primaryCompletion":75,"completion":75,"start":296,"enrollment":297,"conditions":589,"interventions":590},[83],[32],[76,76,275,269,300,301],{"trials":592,"activeCount":205,"soonestReadout":597},[593],{"nctId":594,"briefTitle":595,"status":119,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":605},"NCT06710132","Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)",[83,84],"2027-12-23","2025-01-29",250,[21,601,602,603,604],"Gastric Cancer","Non-Small Cell Lung Cancer (NSCLC)","Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)",[76],{"trials":607,"activeCount":94},[],{"trials":609,"activeCount":94},[],{"trials":611,"activeCount":94},[],{"intervention":169,"totalTrials":170,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":622,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":615,"activeCount":94},[],{"trials":617,"activeCount":205,"soonestReadout":80},[618],{"nctId":78,"briefTitle":79,"status":119,"phases":619,"primaryCompletion":80,"completion":80,"start":164,"enrollment":165,"conditions":620,"interventions":621},[83],[167],[54,169,49],{"trials":623,"activeCount":205,"soonestReadout":53},[624],{"nctId":51,"briefTitle":52,"status":119,"phases":625,"primaryCompletion":53,"completion":457,"start":458,"enrollment":459,"conditions":626,"interventions":627},[84],[24],[54,462,169],{"trials":629,"activeCount":94},[],{"trials":631,"activeCount":94},[],{"trials":633,"activeCount":94},[],{"intervention":192,"totalTrials":170,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":651,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":637,"activeCount":94},[],{"trials":639,"activeCount":94},[640],{"nctId":641,"briefTitle":642,"status":100,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT04457778","First in Human Study of M6223",[83],"2023-06-23","2020-07-10",58,[648],"Metastatic Solid Tumors",[192,650,192],"Bintrafusp alfa",{"trials":652,"activeCount":205,"soonestReadout":48},[653],{"nctId":46,"briefTitle":47,"status":119,"phases":654,"primaryCompletion":48,"completion":186,"start":155,"enrollment":187,"conditions":655,"interventions":656},[84],[189],[49,191,192,193],{"trials":658,"activeCount":94},[],{"trials":660,"activeCount":94},[],{"trials":662,"activeCount":94},[],{"intervention":514,"totalTrials":205,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":94},[],{"trials":668,"activeCount":94},[],{"trials":670,"activeCount":205,"soonestReadout":44},[671],{"nctId":42,"briefTitle":43,"status":119,"phases":672,"primaryCompletion":44,"completion":508,"start":509,"enrollment":510,"conditions":673,"interventions":674},[84],[512],[40,514],{"trials":676,"activeCount":94},[],{"trials":678,"activeCount":94},[],{"trials":680,"activeCount":94},[],{"intervention":574,"totalTrials":205,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":94},[],{"trials":686,"activeCount":94},[],{"trials":688,"activeCount":205,"soonestReadout":71},[689],{"nctId":69,"briefTitle":70,"status":119,"phases":690,"primaryCompletion":71,"completion":71,"start":569,"enrollment":570,"conditions":691,"interventions":692},[83,84],[572],[63,574],{"trials":694,"activeCount":94},[],{"trials":696,"activeCount":94},[],{"trials":698,"activeCount":94},[],{"intervention":191,"totalTrials":205,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":702,"activeCount":94},[],{"trials":704,"activeCount":94},[],{"trials":706,"activeCount":205,"soonestReadout":48},[707],{"nctId":46,"briefTitle":47,"status":119,"phases":708,"primaryCompletion":48,"completion":186,"start":155,"enrollment":187,"conditions":709,"interventions":710},[84],[189],[49,191,192,193],{"trials":712,"activeCount":94},[],{"trials":714,"activeCount":94},[],{"trials":716,"activeCount":94},[],{"intervention":193,"totalTrials":205,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":720,"activeCount":94},[],{"trials":722,"activeCount":94},[],{"trials":724,"activeCount":205,"soonestReadout":48},[725],{"nctId":46,"briefTitle":47,"status":119,"phases":726,"primaryCompletion":48,"completion":186,"start":155,"enrollment":187,"conditions":727,"interventions":728},[84],[189],[49,191,192,193],{"trials":730,"activeCount":94},[],{"trials":732,"activeCount":94},[],{"trials":734,"activeCount":94},[],{"intervention":269,"totalTrials":104,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":745,"PHASE3":761,"PHASE4":767,"NA":769},{"trials":738,"activeCount":94},[],{"trials":740,"activeCount":205,"soonestReadout":75},[741],{"nctId":73,"briefTitle":74,"status":294,"phases":742,"primaryCompletion":75,"completion":75,"start":296,"enrollment":297,"conditions":743,"interventions":744},[83],[32],[76,76,275,269,300,301],{"trials":746,"activeCount":94},[747],{"nctId":748,"briefTitle":749,"status":100,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":754,"interventions":756},"NCT03770689","Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer",[83,84],"2021-06-21","2022-02-21","2019-03-20",[755],"Locally Advanced Rectal Cancer",[757,758,759,760,269],"Peposertib 50 mg","Peposertib 100 mg","Peposertib 150 mg","Peposertib 250 mg",{"trials":762,"activeCount":94},[763],{"nctId":256,"briefTitle":257,"status":100,"phases":764,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":765,"interventions":766},[85],[264],[49,266,267,268,269,266,267,268,269],{"trials":768,"activeCount":94},[],{"trials":770,"activeCount":94},[],{"intervention":772,"totalTrials":170,"cells":773},"Pembrolizumab",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":789,"PHASE3":791,"PHASE4":803,"NA":805},{"trials":775,"activeCount":94},[],{"trials":777,"activeCount":205,"soonestReadout":782},[778],{"nctId":779,"briefTitle":780,"status":294,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":786},"NCT07166601","M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors",[83],"2029-02-23","2025-10-10",77,[18],[787,787,772,788],"M0324","mFOLFIRINOX",{"trials":790,"activeCount":94},[],{"trials":792,"activeCount":94},[793],{"nctId":794,"briefTitle":795,"status":100,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":802},"NCT03631706","M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)",[85],"2021-06-07","2024-06-25","2018-10-01",304,[512],[292,772],{"trials":804,"activeCount":94},[],{"trials":806,"activeCount":94},[],{"intervention":300,"totalTrials":170,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":817,"PHASE3":819,"PHASE4":825,"NA":827},{"trials":810,"activeCount":94},[],{"trials":812,"activeCount":205,"soonestReadout":75},[813],{"nctId":73,"briefTitle":74,"status":294,"phases":814,"primaryCompletion":75,"completion":75,"start":296,"enrollment":297,"conditions":815,"interventions":816},[83],[32],[76,76,275,269,300,301],{"trials":818,"activeCount":94},[],{"trials":820,"activeCount":94},[821],{"nctId":256,"briefTitle":257,"status":100,"phases":822,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":823,"interventions":824},[85],[264],[49,266,267,268,269,266,267,268,269],{"trials":826,"activeCount":94},[],{"trials":828,"activeCount":94},[],{"intervention":310,"totalTrials":104,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":832,"activeCount":94},[],{"trials":834,"activeCount":205,"soonestReadout":438},[835,839,849],{"nctId":435,"briefTitle":436,"status":119,"phases":836,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":837,"interventions":838},[83],[18],[310,54,443,444],{"nctId":840,"briefTitle":841,"status":176,"phases":842,"primaryCompletion":843,"completion":843,"start":843,"enrollment":94,"conditions":844,"interventions":845},"NCT06719973","Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)",[83],"2025-05-14",[27],[310,108,846,847,848,848,108],"Etoposide","Atezolizumab","M9446",{"nctId":303,"briefTitle":304,"status":131,"phases":850,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":851,"interventions":852},[83],[18],[310,238,301,311,275,312],{"trials":854,"activeCount":94},[],{"trials":856,"activeCount":94},[],{"trials":858,"activeCount":94},[],{"trials":860,"activeCount":94},[],{"intervention":301,"totalTrials":170,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":864,"activeCount":94},[],{"trials":866,"activeCount":205,"soonestReadout":75},[867,871],{"nctId":73,"briefTitle":74,"status":294,"phases":868,"primaryCompletion":75,"completion":75,"start":296,"enrollment":297,"conditions":869,"interventions":870},[83],[32],[76,76,275,269,300,301],{"nctId":303,"briefTitle":304,"status":131,"phases":872,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":873,"interventions":874},[83],[18],[310,238,301,311,275,312],{"trials":876,"activeCount":94},[],{"trials":878,"activeCount":94},[],{"trials":880,"activeCount":94},[],{"trials":882,"activeCount":94},[],{"intervention":787,"totalTrials":205,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":886,"activeCount":94},[],{"trials":888,"activeCount":205,"soonestReadout":782},[889],{"nctId":779,"briefTitle":780,"status":294,"phases":890,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":891,"interventions":892},[83],[18],[787,787,772,788],{"trials":894,"activeCount":94},[],{"trials":896,"activeCount":94},[],{"trials":898,"activeCount":94},[],{"trials":900,"activeCount":94},[],{"intervention":788,"totalTrials":205,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":904,"activeCount":94},[],{"trials":906,"activeCount":205,"soonestReadout":782},[907],{"nctId":779,"briefTitle":780,"status":294,"phases":908,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":909,"interventions":910},[83],[18],[787,787,772,788],{"trials":912,"activeCount":94},[],{"trials":914,"activeCount":94},[],{"trials":916,"activeCount":94},[],{"trials":918,"activeCount":94},[],{"intervention":443,"totalTrials":205,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":94},[],{"trials":924,"activeCount":205,"soonestReadout":438},[925],{"nctId":435,"briefTitle":436,"status":119,"phases":926,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":927,"interventions":928},[83],[18],[310,54,443,444],{"trials":930,"activeCount":94},[],{"trials":932,"activeCount":94},[],{"trials":934,"activeCount":94},[],{"trials":936,"activeCount":94},[],{"intervention":444,"totalTrials":205,"cells":938},{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":940,"activeCount":94},[],{"trials":942,"activeCount":205,"soonestReadout":438},[943],{"nctId":435,"briefTitle":436,"status":119,"phases":944,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":945,"interventions":946},[83],[18],[310,54,443,444],{"trials":948,"activeCount":94},[],{"trials":950,"activeCount":94},[],{"trials":952,"activeCount":94},[],{"trials":954,"activeCount":94},[],{"intervention":956,"totalTrials":205,"cells":957},"M3554",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":959,"activeCount":94},[],{"trials":961,"activeCount":205,"soonestReadout":966},[962],{"nctId":963,"briefTitle":964,"status":294,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":135,"conditions":968,"interventions":969},"NCT06641908","Anti-GD2 ADC M3554 in Advanced Solid Tumors",[83],"2027-04-16","2024-11-08",[18],[956],{"trials":971,"activeCount":94},[],{"trials":973,"activeCount":94},[],{"trials":975,"activeCount":94},[],{"trials":977,"activeCount":94},[],{"intervention":127,"totalTrials":205,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":981,"activeCount":94},[],{"trials":983,"activeCount":205,"soonestReadout":58},[984],{"nctId":56,"briefTitle":57,"status":119,"phases":985,"primaryCompletion":58,"completion":121,"start":122,"enrollment":123,"conditions":986,"interventions":987},[83],[125],[49,127],{"trials":989,"activeCount":94},[],{"trials":991,"activeCount":94},[],{"trials":993,"activeCount":94},[],{"trials":995,"activeCount":94},[],{"intervention":997,"totalTrials":205,"cells":998},"M7437",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1000,"activeCount":94},[],{"trials":1002,"activeCount":205,"soonestReadout":1007},[1003],{"nctId":1004,"briefTitle":1005,"status":294,"phases":1006,"primaryCompletion":1007,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1012},"NCT07360314","Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors",[83],"2028-09-20","2029-03-28","2026-02-13",138,[27],[997,997],{"trials":1014,"activeCount":94},[],{"trials":1016,"activeCount":94},[],{"trials":1018,"activeCount":94},[],{"trials":1020,"activeCount":94},[],{"intervention":1022,"totalTrials":170,"cells":1023},"Rebif",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1052},{"trials":1025,"activeCount":94},[],{"trials":1027,"activeCount":94},[],{"trials":1029,"activeCount":94},[],{"trials":1031,"activeCount":94},[],{"trials":1033,"activeCount":94},[1034,1044],{"nctId":1035,"briefTitle":1036,"status":100,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1043},"NCT01085318","Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial",[86],"2012-02-29","2012-03-31","2010-06-30",38,[15],[1022],{"nctId":1045,"briefTitle":1046,"status":176,"phases":1047,"start":1048,"enrollment":94,"conditions":1049,"interventions":1051},"NCT00101959","Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects",[86],"2004-11",[1050],"Relapsing-Remitting Multiple Sclerosis",[1022],{"trials":1053,"activeCount":94},[],{"intervention":1055,"totalTrials":170,"cells":1056},"Recombinant human follicle stimulating hormone",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1094},{"trials":1058,"activeCount":94},[],{"trials":1060,"activeCount":94},[],{"trials":1062,"activeCount":94},[],{"trials":1064,"activeCount":94},[],{"trials":1066,"activeCount":94},[1067,1081],{"nctId":1068,"briefTitle":1069,"status":100,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT00298025","A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation",[86],"2004-05","2003-09",185,[1075],"Infertile Women Undergoing Assisted Reproductive Technology (ART)",[1077,1078,1055,1079,1080],"Cetrotide®","Antagon ™","Human Menopausal Gonadotropin","Recombinant Human Choriogonadotropin",{"nctId":1082,"briefTitle":1083,"status":131,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1090},"NCT00328926","Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [\u003C] 1.2 International Unit Per Liter [IU\u002FL])",[86],"2012-05","2006-03",11,[1089],"Hypogonadotropic Hypogonadism",[1091,1092,1055,1093],"Luveris® 75 IU","Luveris® 25 IU","Recombinant human chorionic gonadotropin",{"trials":1095,"activeCount":94},[],{"intervention":1097,"totalTrials":205,"cells":1098},"Copaxone®",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1119},{"trials":1100,"activeCount":94},[],{"trials":1102,"activeCount":94},[],{"trials":1104,"activeCount":94},[],{"trials":1106,"activeCount":94},[],{"trials":1108,"activeCount":94},[1109],{"nctId":1110,"briefTitle":1111,"status":100,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1117},"NCT00078338","Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis",[86],"2006-11-28","2004-02-16",764,[34],[1118,1097],"Rebif®",{"trials":1120,"activeCount":94},[],{"intervention":1077,"totalTrials":205,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1137},{"trials":1124,"activeCount":94},[],{"trials":1126,"activeCount":94},[],{"trials":1128,"activeCount":94},[],{"trials":1130,"activeCount":94},[],{"trials":1132,"activeCount":94},[1133],{"nctId":1068,"briefTitle":1069,"status":100,"phases":1134,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1135,"interventions":1136},[86],[1075],[1077,1078,1055,1079,1080],{"trials":1138,"activeCount":94},[],{"intervention":1078,"totalTrials":205,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1155},{"trials":1142,"activeCount":94},[],{"trials":1144,"activeCount":94},[],{"trials":1146,"activeCount":94},[],{"trials":1148,"activeCount":94},[],{"trials":1150,"activeCount":94},[1151],{"nctId":1068,"briefTitle":1069,"status":100,"phases":1152,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1153,"interventions":1154},[86],[1075],[1077,1078,1055,1079,1080],{"trials":1156,"activeCount":94},[],{"intervention":1079,"totalTrials":205,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1173},{"trials":1160,"activeCount":94},[],{"trials":1162,"activeCount":94},[],{"trials":1164,"activeCount":94},[],{"trials":1166,"activeCount":94},[],{"trials":1168,"activeCount":94},[1169],{"nctId":1068,"briefTitle":1069,"status":100,"phases":1170,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1171,"interventions":1172},[86],[1075],[1077,1078,1055,1079,1080],{"trials":1174,"activeCount":94},[],{"intervention":1080,"totalTrials":205,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1191},{"trials":1178,"activeCount":94},[],{"trials":1180,"activeCount":94},[],{"trials":1182,"activeCount":94},[],{"trials":1184,"activeCount":94},[],{"trials":1186,"activeCount":94},[1187],{"nctId":1068,"briefTitle":1069,"status":100,"phases":1188,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1189,"interventions":1190},[86],[1075],[1077,1078,1055,1079,1080],{"trials":1192,"activeCount":94},[],{"intervention":1091,"totalTrials":205,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1209},{"trials":1196,"activeCount":94},[],{"trials":1198,"activeCount":94},[],{"trials":1200,"activeCount":94},[],{"trials":1202,"activeCount":94},[],{"trials":1204,"activeCount":94},[1205],{"nctId":1082,"briefTitle":1083,"status":131,"phases":1206,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1207,"interventions":1208},[86],[1089],[1091,1092,1055,1093],{"trials":1210,"activeCount":94},[],{"intervention":1092,"totalTrials":205,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1227},{"trials":1214,"activeCount":94},[],{"trials":1216,"activeCount":94},[],{"trials":1218,"activeCount":94},[],{"trials":1220,"activeCount":94},[],{"trials":1222,"activeCount":94},[1223],{"nctId":1082,"briefTitle":1083,"status":131,"phases":1224,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1225,"interventions":1226},[86],[1089],[1091,1092,1055,1093],{"trials":1228,"activeCount":94},[],{"intervention":1093,"totalTrials":205,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1245},{"trials":1232,"activeCount":94},[],{"trials":1234,"activeCount":94},[],{"trials":1236,"activeCount":94},[],{"trials":1238,"activeCount":94},[],{"trials":1240,"activeCount":94},[1241],{"nctId":1082,"briefTitle":1083,"status":131,"phases":1242,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1243,"interventions":1244},[86],[1089],[1091,1092,1055,1093],{"trials":1246,"activeCount":94},[],{"intervention":253,"totalTrials":19,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1298,"PHASE3":1320,"PHASE4":1349,"NA":1351},{"trials":1250,"activeCount":94},[],{"trials":1252,"activeCount":94},[1253,1261,1275,1285,1289],{"nctId":1254,"briefTitle":1255,"status":100,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":1259,"interventions":1260},"NCT02157792","M6620 First in Human Study",[83],"2020-03-11","2012-12-10",[18],[107,252,253,846,108,238],{"nctId":1262,"briefTitle":1263,"status":100,"phases":1264,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":1268,"interventions":1269},"NCT02516813","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",[83],"2021-03-26","2021-11-19","2015-09-15",[27],[1270,1271,1272,1273,1274,253],"M3814 100 mg","M3814 200 mg","M3814 300 mg","M3814 400 mg","M3814 50 mg",{"nctId":1276,"briefTitle":1277,"status":131,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":16,"conditions":1281,"interventions":1283},"NCT06056310","Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)",[83],"2024-08-20","2024-01-18",[1282],"Head and Neck Cancer",[1284,253],"Xevinapant",{"nctId":282,"briefTitle":283,"status":100,"phases":1286,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":1287,"interventions":1288},[83],[290],[292,108,239,275,253],{"nctId":1290,"briefTitle":1291,"status":131,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":170,"conditions":1295,"interventions":1297},"NCT03116971","Phase Ib\u002FII Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)",[83],"2018-03-01","2017-05-25",[1296],"Small Cell Lung Cancer",[161,253,846],{"trials":1299,"activeCount":94},[1300,1310],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1308},"NCT03840915","M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)",[83,84],"2022-07-29","2019-04-02",70,[217],[253,108,251,1309,252,219,292,108,108,650,239],"Nab-paclitaxel",{"nctId":1311,"briefTitle":1312,"status":131,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1318},"NCT03840902","M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)",[84],"2023-02-17","2019-04-16",153,[512],[292,1319,846,251,108,239,253],"Durvalumab",{"trials":1321,"activeCount":94},[1322,1332,1345],{"nctId":1323,"briefTitle":1324,"status":131,"phases":1325,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT04459715","A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)",[85],"2024-09-18","2020-08-07",730,[1330],"Squamous Cell Carcinoma of the Head and Neck",[1284,253],{"nctId":1333,"briefTitle":1334,"status":131,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1344},"NCT04066491","Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC",[84,85],"2021-05-20","2022-11-10","2019-09-20",309,[1341,1342,1343],"Biliary Tract Cancer","Cholangiocarcinoma","Gallbladder Cancer",[292,252,253],{"nctId":241,"briefTitle":242,"status":100,"phases":1346,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1347,"interventions":1348},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":1350,"activeCount":94},[],{"trials":1352,"activeCount":94},[],{"intervention":108,"totalTrials":22,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1402,"PHASE3":1412,"PHASE4":1418,"NA":1420},{"trials":1356,"activeCount":94},[],{"trials":1358,"activeCount":94},[1359,1363,1390,1394,1398],{"nctId":1254,"briefTitle":1255,"status":100,"phases":1360,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":1361,"interventions":1362},[83],[18],[107,252,253,846,108,238],{"nctId":1364,"briefTitle":1365,"status":100,"phases":1366,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1373},"NCT02278250","First in Human Study of M4344 in Participants With Advanced Solid Tumors",[83],"2021-06-16","2021-09-24","2015-01-26",97,[1372,18],"Solid Tumor",[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],"M4344 10 mg BIW","M4344 20 mg BIW","M4344 40 mg BIW","M4344 80 mg BIW","M4344 160 mg BIW","M4344 300 mg BIW","M4344 450 mg BIW","M4344 700 mg BIW","M4344 1050 mg BIW","M4344 1200 mg BIW","M4344 100 mg BID","M4344 150 mg QD","M4344 250 mg QD","M4344 350 mg QD","M4344 400 mg","M4344 500 mg",{"nctId":840,"briefTitle":841,"status":176,"phases":1391,"primaryCompletion":843,"completion":843,"start":843,"enrollment":94,"conditions":1392,"interventions":1393},[83],[27],[310,108,846,847,848,848,108],{"nctId":98,"briefTitle":99,"status":100,"phases":1395,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":1396,"interventions":1397},[83],[24],[107,49,108],{"nctId":282,"briefTitle":283,"status":100,"phases":1399,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":1400,"interventions":1401},[83],[290],[292,108,239,275,253],{"trials":1403,"activeCount":94},[1404,1408],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1405,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1406,"interventions":1407},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1311,"briefTitle":1312,"status":131,"phases":1409,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1410,"interventions":1411},[84],[512],[292,1319,846,251,108,239,253],{"trials":1413,"activeCount":94},[1414],{"nctId":241,"briefTitle":242,"status":100,"phases":1415,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1416,"interventions":1417},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":1419,"activeCount":94},[],{"trials":1421,"activeCount":94},[],{"intervention":1423,"totalTrials":1424,"cells":1425},"Atacicept",7,{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1439,"PHASE3":1489,"PHASE4":1501,"NA":1503},{"trials":1427,"activeCount":94},[],{"trials":1429,"activeCount":94},[1430],{"nctId":1431,"briefTitle":1432,"status":131,"phases":1433,"primaryCompletion":1434,"start":1435,"enrollment":205,"conditions":1436,"interventions":1438},"NCT01369628","Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil",[83],"2011-11","2011-06",[1437],"Lupus Nephritis",[1423],{"trials":1440,"activeCount":94},[1441,1451,1461,1468,1478],{"nctId":1442,"briefTitle":1443,"status":176,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":94,"conditions":1448,"interventions":1450},"NCT01440231","Atacicept Demonstrating Dose RESponSe",[84],"2013-08","2014-02","2012-02",[1449],"Systemic Lupus Erythematosus",[1423,1423,1423,1423],{"nctId":1452,"briefTitle":1453,"status":131,"phases":1454,"primaryCompletion":1455,"completion":1455,"start":1456,"enrollment":1457,"conditions":1458,"interventions":1460},"NCT00642902","A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)",[84],"2009-09","2008-04",255,[1459],"Relapsing Multiple Sclerosis",[1423,1423,1423],{"nctId":1462,"briefTitle":1463,"status":100,"phases":1464,"primaryCompletion":1455,"completion":1455,"start":1465,"enrollment":187,"conditions":1466,"interventions":1467},"NCT00430495","A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)",[84],"2006-12",[29],[1423,1423,1423],{"nctId":1469,"briefTitle":1470,"status":131,"phases":1471,"primaryCompletion":1455,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1477},"NCT00624468","Atacicept in Subjects With Optic Neuritis",[84],"2011-01","2008-06",34,[1476],"Optic Neuritis",[1423],{"nctId":1479,"briefTitle":1480,"status":100,"phases":1481,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":1484,"conditions":1485,"interventions":1486},"NCT00595413","Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)",[84],"2009-10","2007-09",311,[29],[1487,1423,1488],"Atacicept: with loading dose","Adalimumab",{"trials":1490,"activeCount":94},[1491],{"nctId":1492,"briefTitle":1493,"status":131,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":25,"conditions":1497,"interventions":1498},"NCT00573157","The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis",[84,85],"2009-04","2007-12",[1437],[1423,1499,1500],"Mycophenolate mofetil","Corticosteroids",{"trials":1502,"activeCount":94},[],{"trials":1504,"activeCount":94},[],{"intervention":292,"totalTrials":25,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1515,"PHASE3":1535,"PHASE4":1545,"NA":1547},{"trials":1508,"activeCount":94},[],{"trials":1510,"activeCount":94},[1511],{"nctId":282,"briefTitle":283,"status":100,"phases":1512,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":1513,"interventions":1514},[83],[290],[292,108,239,275,253],{"trials":1516,"activeCount":94},[1517,1521,1525],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1518,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1519,"interventions":1520},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1311,"briefTitle":1312,"status":131,"phases":1522,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1523,"interventions":1524},[84],[512],[292,1319,846,251,108,239,253],{"nctId":1526,"briefTitle":1527,"status":100,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1534},"NCT03833661","M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)",[84],"2020-11-09","2022-09-30","2019-03-26",159,[1341,1342,1343],[292],{"trials":1536,"activeCount":94},[1537,1541],{"nctId":794,"briefTitle":795,"status":100,"phases":1538,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":1539,"interventions":1540},[85],[512],[292,772],{"nctId":1333,"briefTitle":1334,"status":131,"phases":1542,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1543,"interventions":1544},[84,85],[1341,1342,1343],[292,252,253],{"trials":1546,"activeCount":94},[],{"trials":1548,"activeCount":94},[],{"intervention":252,"totalTrials":1550,"cells":1551},5,{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1560,"PHASE3":1577,"PHASE4":1587,"NA":1589},{"trials":1553,"activeCount":94},[],{"trials":1555,"activeCount":94},[1556],{"nctId":1254,"briefTitle":1255,"status":100,"phases":1557,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":1558,"interventions":1559},[83],[18],[107,252,253,846,108,238],{"trials":1561,"activeCount":94},[1562,1566],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1563,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1564,"interventions":1565},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1567,"briefTitle":1568,"status":100,"phases":1569,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":440,"conditions":1573,"interventions":1575},"NCT01016483","Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer",[83,84],"2013-12-31","2015-04-30","2009-11-30",[1574],"Pancreatic Adenocarcinoma",[1576,252],"Pimasertib",{"trials":1578,"activeCount":94},[1579,1583],{"nctId":1333,"briefTitle":1334,"status":131,"phases":1580,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1581,"interventions":1582},[84,85],[1341,1342,1343],[292,252,253],{"nctId":241,"briefTitle":242,"status":100,"phases":1584,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1585,"interventions":1586},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":1588,"activeCount":94},[],{"trials":1590,"activeCount":94},[],{"intervention":650,"totalTrials":1550,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1601,"PHASE3":1628,"PHASE4":1641,"NA":1643},{"trials":1594,"activeCount":94},[],{"trials":1596,"activeCount":94},[1597],{"nctId":641,"briefTitle":642,"status":100,"phases":1598,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":1599,"interventions":1600},[83],[648],[192,650,192],{"trials":1602,"activeCount":94},[1603,1607,1618],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1604,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1605,"interventions":1606},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1608,"briefTitle":1609,"status":100,"phases":1610,"primaryCompletion":1611,"completion":1612,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1617},"NCT04246489","Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer",[84],"2022-04-05","2022-12-14","2020-03-30",146,[1616],"Uterine Cervical Neoplasms",[650],{"nctId":1619,"briefTitle":1620,"status":131,"phases":1621,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":1087,"conditions":1625,"interventions":1627},"NCT04489940","Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer",[84],"2022-01-27","2022-07-08","2020-10-12",[1626],"Triple Negative Breast Neoplasms",[650],{"trials":1629,"activeCount":94},[1630],{"nctId":1631,"briefTitle":1632,"status":100,"phases":1633,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1640},"NCT05061823","Bintrafusp Alfa Program Rollover Study",[85],"2025-03-21","2021-12-01",22,[1638,1639],"Lung Cancer","Cancer",[650],{"trials":1642,"activeCount":94},[],{"trials":1644,"activeCount":94},[],{"intervention":239,"totalTrials":1550,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1655,"PHASE3":1665,"PHASE4":1675,"NA":1677},{"trials":1648,"activeCount":94},[],{"trials":1650,"activeCount":94},[1651],{"nctId":282,"briefTitle":283,"status":100,"phases":1652,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":1653,"interventions":1654},[83],[290],[292,108,239,275,253],{"trials":1656,"activeCount":94},[1657,1661],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1658,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1659,"interventions":1660},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1311,"briefTitle":1312,"status":131,"phases":1662,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1663,"interventions":1664},[84],[512],[292,1319,846,251,108,239,253],{"trials":1666,"activeCount":94},[1667,1671],{"nctId":227,"briefTitle":228,"status":100,"phases":1668,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":1669,"interventions":1670},[85],[235,236],[49,238,239],{"nctId":241,"briefTitle":242,"status":100,"phases":1672,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1673,"interventions":1674},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":1676,"activeCount":94},[],{"trials":1678,"activeCount":94},[],{"intervention":251,"totalTrials":30,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1707,"PHASE4":1713,"NA":1715},{"trials":1682,"activeCount":94},[],{"trials":1684,"activeCount":94},[],{"trials":1686,"activeCount":94},[1687,1691,1695],{"nctId":1301,"briefTitle":1302,"status":100,"phases":1688,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1689,"interventions":1690},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"nctId":1311,"briefTitle":1312,"status":131,"phases":1692,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1693,"interventions":1694},[84],[512],[292,1319,846,251,108,239,253],{"nctId":1696,"briefTitle":1697,"status":100,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1705},"NCT00111839","Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer",[84],"2007-07-31","2009-03-31","2005-05-31",150,[1638,1704],"Non Small Cell Lung Carcinoma",[251,1706],"Matuzumab",{"trials":1708,"activeCount":94},[1709],{"nctId":241,"briefTitle":242,"status":100,"phases":1710,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1711,"interventions":1712},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":1714,"activeCount":94},[],{"trials":1716,"activeCount":94},[],{"intervention":1718,"totalTrials":30,"cells":1719},"Atacicept 150 mg",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1759,"PHASE4":1771,"NA":1773},{"trials":1721,"activeCount":94},[],{"trials":1723,"activeCount":94},[],{"trials":1725,"activeCount":94},[1726,1738,1749],{"nctId":1727,"briefTitle":1728,"status":100,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1736},"NCT01972568","Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus",[84],"2016-04","2016-09","2013-12",306,[1735],"Lupus Erythematosus, Systemic",[1737,1718],"Atacicept 75 milligram",{"nctId":1739,"briefTitle":1740,"status":131,"phases":1741,"primaryCompletion":1455,"completion":1742,"start":1743,"enrollment":1744,"conditions":1745,"interventions":1746},"NCT00853762","Atacicept in Multiple Sclerosis Extension Study, Phase II",[84],"2011-02","2009-03",74,[1459],[1747,1748,1718,1718],"Atacicept 25 mg","Atacicept 75 mg",{"nctId":1750,"briefTitle":1751,"status":131,"phases":1752,"primaryCompletion":1753,"completion":1754,"start":1755,"enrollment":1756,"conditions":1757,"interventions":1758},"NCT02070978","Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)",[84],"2016-04-05","2018-02-09","2014-07-29",253,[1735],[1748,1718,1718],{"trials":1760,"activeCount":94},[1761],{"nctId":1762,"briefTitle":1763,"status":100,"phases":1764,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1770},"NCT00624338","Atacicept Phase 2\u002F3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)",[84,85],"2012-04","2012-10","2008-01",461,[1735],[1748,1718],{"trials":1772,"activeCount":94},[],{"trials":1774,"activeCount":94},[],{"intervention":1748,"totalTrials":30,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1800,"PHASE4":1806,"NA":1808},{"trials":1778,"activeCount":94},[],{"trials":1780,"activeCount":94},[],{"trials":1782,"activeCount":94},[1783,1792,1796],{"nctId":1784,"briefTitle":1785,"status":131,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":134,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT02808429","Efficacy and Safety of Atacicept in IgA Nephropathy",[84],"2020-02-07",16,[1790],"IgA Nephropathy",[1747,1748],{"nctId":1739,"briefTitle":1740,"status":131,"phases":1793,"primaryCompletion":1455,"completion":1742,"start":1743,"enrollment":1744,"conditions":1794,"interventions":1795},[84],[1459],[1747,1748,1718,1718],{"nctId":1750,"briefTitle":1751,"status":131,"phases":1797,"primaryCompletion":1753,"completion":1754,"start":1755,"enrollment":1756,"conditions":1798,"interventions":1799},[84],[1735],[1748,1718,1718],{"trials":1801,"activeCount":94},[1802],{"nctId":1762,"briefTitle":1763,"status":100,"phases":1803,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1804,"interventions":1805},[84,85],[1735],[1748,1718],{"trials":1807,"activeCount":94},[],{"trials":1809,"activeCount":94},[],{"intervention":238,"totalTrials":104,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1824,"PHASE3":1826,"PHASE4":1832,"NA":1834},{"trials":1813,"activeCount":94},[],{"trials":1815,"activeCount":94},[1816,1820],{"nctId":1254,"briefTitle":1255,"status":100,"phases":1817,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":1818,"interventions":1819},[83],[18],[107,252,253,846,108,238],{"nctId":303,"briefTitle":304,"status":131,"phases":1821,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":1822,"interventions":1823},[83],[18],[310,238,301,311,275,312],{"trials":1825,"activeCount":94},[],{"trials":1827,"activeCount":94},[1828],{"nctId":227,"briefTitle":228,"status":100,"phases":1829,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":1830,"interventions":1831},[85],[235,236],[49,238,239],{"trials":1833,"activeCount":94},[],{"trials":1835,"activeCount":94},[],{"intervention":1837,"totalTrials":104,"cells":1838},"Evobrutinib",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1856,"PHASE4":1877,"NA":1879},{"trials":1840,"activeCount":94},[],{"trials":1842,"activeCount":94},[],{"trials":1844,"activeCount":94},[1845],{"nctId":1846,"briefTitle":1847,"status":131,"phases":1848,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1854},"NCT02975349","A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis",[84],"2018-01-24","2024-04-02","2017-03-07",267,[34],[1837,1837,1837,1855],"Tecfidera",{"trials":1857,"activeCount":94},[1858,1869],{"nctId":1859,"briefTitle":1860,"status":131,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":205,"conditions":1864,"interventions":1865},"NCT04032171","Study of Evobrutinib in Participants With RMS",[85],"2020-05-20","2019-09-10",[34],[1837,1866,1867,1868],"Avonex®","Avonex® matched Placebo","Evobrutinib matched Placebo",{"nctId":1870,"briefTitle":1871,"status":131,"phases":1872,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":104,"conditions":1875,"interventions":1876},"NCT04032158","Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)",[85],"2020-04-16","2019-08-26",[34],[1837,1866,1867,1868],{"trials":1878,"activeCount":94},[],{"trials":1880,"activeCount":94},[],{"intervention":1882,"totalTrials":104,"cells":1883},"Tecemotide",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1902,"PHASE4":1924,"NA":1926},{"trials":1885,"activeCount":94},[],{"trials":1887,"activeCount":94},[],{"trials":1889,"activeCount":94},[1890],{"nctId":1891,"briefTitle":1892,"status":100,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1897,"interventions":1899},"NCT01496131","Tecemotide (L-BLP25) in Prostate Cancer",[84],"2016-11-25","2011-10-24",28,[1898],"Prostate Cancer",[1900,1901,1882],"Goserelin","Cyclophosphamide",{"trials":1903,"activeCount":94},[1904,1914],{"nctId":1905,"briefTitle":1906,"status":131,"phases":1907,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":1910,"conditions":1911,"interventions":1912},"NCT02049151","Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer",[85],"2015-07","2014-03",35,[217],[1882,1901,1913],"Saline",{"nctId":1915,"briefTitle":1916,"status":100,"phases":1917,"primaryCompletion":1765,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1922},"NCT00409188","Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)",[85],"2015-04","2007-01",1513,[512],[1882,1923],"Single low dose cyclophosphamide",{"trials":1925,"activeCount":94},[],{"trials":1927,"activeCount":94},[],{"intervention":1901,"totalTrials":104,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1940,"PHASE4":1956,"NA":1958},{"trials":1931,"activeCount":94},[],{"trials":1933,"activeCount":94},[],{"trials":1935,"activeCount":94},[1936],{"nctId":1891,"briefTitle":1892,"status":100,"phases":1937,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1938,"interventions":1939},[84],[1898],[1900,1901,1882],{"trials":1941,"activeCount":94},[1942,1946],{"nctId":1905,"briefTitle":1906,"status":131,"phases":1943,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":1910,"conditions":1944,"interventions":1945},[85],[217],[1882,1901,1913],{"nctId":1947,"briefTitle":1948,"status":131,"phases":1949,"primaryCompletion":1950,"completion":1950,"start":1455,"enrollment":1788,"conditions":1951,"interventions":1952},"NCT00925548","STRIDE - STimulating Immune Response In aDvanced brEast Cancer",[85],"2010-08",[546],[1953,1954,1955],"Tecemotide (L-BLP25) and Hormonal Treatment","cyclophosphamide","sodium chloride",{"trials":1957,"activeCount":94},[],{"trials":1959,"activeCount":94},[],{"intervention":1284,"totalTrials":104,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1970,"PHASE3":1972,"PHASE4":1987,"NA":1989},{"trials":1963,"activeCount":94},[],{"trials":1965,"activeCount":94},[1966],{"nctId":1276,"briefTitle":1277,"status":131,"phases":1967,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":16,"conditions":1968,"interventions":1969},[83],[1282],[1284,253],{"trials":1971,"activeCount":94},[],{"trials":1973,"activeCount":94},[1974,1983],{"nctId":1975,"briefTitle":1976,"status":131,"phases":1977,"primaryCompletion":1978,"completion":1978,"start":1979,"enrollment":1980,"conditions":1981,"interventions":1982},"NCT05386550","Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)",[85],"2024-08-27","2022-10-06",166,[1282],[1284],{"nctId":1323,"briefTitle":1324,"status":131,"phases":1984,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1985,"interventions":1986},[85],[1330],[1284,253],{"trials":1988,"activeCount":94},[],{"trials":1990,"activeCount":94},[],{"intervention":1866,"totalTrials":104,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":1999,"PHASE4":2019,"NA":2021},{"trials":1994,"activeCount":94},[],{"trials":1996,"activeCount":94},[],{"trials":1998,"activeCount":94},[],{"trials":2000,"activeCount":94},[2001,2005,2009],{"nctId":1859,"briefTitle":1860,"status":131,"phases":2002,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":205,"conditions":2003,"interventions":2004},[85],[34],[1837,1866,1867,1868],{"nctId":1870,"briefTitle":1871,"status":131,"phases":2006,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":104,"conditions":2007,"interventions":2008},[85],[34],[1837,1866,1867,1868],{"nctId":2010,"briefTitle":2011,"status":100,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT00292266","A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)",[85],"2002-06","1999-11",677,[2017],"Multiple Sclerosis, Relapsing-Remitting",[1118,1866],{"trials":2020,"activeCount":94},[],{"trials":2022,"activeCount":94},[],{"intervention":2024,"totalTrials":170,"cells":2025},"Sarizotan",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2053,"NA":2055},{"trials":2027,"activeCount":94},[],{"trials":2029,"activeCount":94},[],{"trials":2031,"activeCount":94},[],{"trials":2033,"activeCount":94},[2034,2045],{"nctId":2035,"briefTitle":2036,"status":100,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2044},"NCT00105521","Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia",[85],"2006-03-31","2004-09-30",398,[2042,2043],"Parkinson's Disease","Dyskinesia",[2024],{"nctId":2046,"briefTitle":2047,"status":100,"phases":2048,"primaryCompletion":2049,"completion":2049,"start":2039,"enrollment":2050,"conditions":2051,"interventions":2052},"NCT00105508","Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia",[85],"2006-02-28",506,[2042,2043],[2024],{"trials":2054,"activeCount":94},[],{"trials":2056,"activeCount":94},[],{"intervention":2058,"totalTrials":170,"cells":2059},"Serostim®",{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2088,"NA":2090},{"trials":2061,"activeCount":94},[],{"trials":2063,"activeCount":94},[],{"trials":2065,"activeCount":94},[],{"trials":2067,"activeCount":94},[2068,2079],{"nctId":2069,"briefTitle":2070,"status":100,"phases":2071,"primaryCompletion":2072,"completion":2072,"start":2073,"enrollment":2074,"conditions":2075,"interventions":2078},"NCT00294918","An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome",[84,85],"2003-02","2001-09",142,[2076,2077],"Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)","Human Immunodeficiency Virus Infections",[2058],{"nctId":2080,"briefTitle":2081,"status":100,"phases":2082,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2087},"NCT00294164","Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)",[84,85],"2002-05","2001-03",245,[2076,2077],[2058],{"trials":2089,"activeCount":94},[],{"trials":2091,"activeCount":94},[],{"intervention":219,"totalTrials":170,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2104,"PHASE4":2110,"NA":2112},{"trials":2095,"activeCount":94},[],{"trials":2097,"activeCount":94},[],{"trials":2099,"activeCount":94},[2100],{"nctId":1301,"briefTitle":1302,"status":100,"phases":2101,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":2102,"interventions":2103},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"trials":2105,"activeCount":94},[2106],{"nctId":209,"briefTitle":210,"status":100,"phases":2107,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":2108,"interventions":2109},[85],[217],[49,219],{"trials":2111,"activeCount":94},[],{"trials":2113,"activeCount":94},[],{"intervention":2115,"totalTrials":170,"cells":2116},"Cilengitide",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2134,"PHASE4":2145,"NA":2147},{"trials":2118,"activeCount":94},[],{"trials":2120,"activeCount":94},[],{"trials":2122,"activeCount":94},[2123],{"nctId":2124,"briefTitle":2125,"status":100,"phases":2126,"primaryCompletion":2127,"completion":1445,"start":1743,"enrollment":2128,"conditions":2129,"interventions":2131},"NCT00813943","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status",[84],"2013-02",265,[2130],"Glioblastoma",[2115,2132,2133],"cilengitide","Temozolomide",{"trials":2135,"activeCount":94},[2136],{"nctId":2137,"briefTitle":2138,"status":100,"phases":2139,"primaryCompletion":2140,"completion":1445,"start":2141,"enrollment":2142,"conditions":2143,"interventions":2144},"NCT00689221","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",[85],"2012-11","2008-09",545,[2130],[2115,2133],{"trials":2146,"activeCount":94},[],{"trials":2148,"activeCount":94},[],{"intervention":2133,"totalTrials":170,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2161,"PHASE4":2167,"NA":2169},{"trials":2152,"activeCount":94},[],{"trials":2154,"activeCount":94},[],{"trials":2156,"activeCount":94},[2157],{"nctId":2124,"briefTitle":2125,"status":100,"phases":2158,"primaryCompletion":2127,"completion":1445,"start":1743,"enrollment":2128,"conditions":2159,"interventions":2160},[84],[2130],[2115,2132,2133],{"trials":2162,"activeCount":94},[2163],{"nctId":2137,"briefTitle":2138,"status":100,"phases":2164,"primaryCompletion":2140,"completion":1445,"start":2141,"enrollment":2142,"conditions":2165,"interventions":2166},[85],[2130],[2115,2133],{"trials":2168,"activeCount":94},[],{"trials":2170,"activeCount":94},[],{"intervention":1867,"totalTrials":170,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2189,"NA":2191},{"trials":2174,"activeCount":94},[],{"trials":2176,"activeCount":94},[],{"trials":2178,"activeCount":94},[],{"trials":2180,"activeCount":94},[2181,2185],{"nctId":1859,"briefTitle":1860,"status":131,"phases":2182,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":205,"conditions":2183,"interventions":2184},[85],[34],[1837,1866,1867,1868],{"nctId":1870,"briefTitle":1871,"status":131,"phases":2186,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":104,"conditions":2187,"interventions":2188},[85],[34],[1837,1866,1867,1868],{"trials":2190,"activeCount":94},[],{"trials":2192,"activeCount":94},[],{"intervention":1868,"totalTrials":170,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2211,"NA":2213},{"trials":2196,"activeCount":94},[],{"trials":2198,"activeCount":94},[],{"trials":2200,"activeCount":94},[],{"trials":2202,"activeCount":94},[2203,2207],{"nctId":1859,"briefTitle":1860,"status":131,"phases":2204,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":205,"conditions":2205,"interventions":2206},[85],[34],[1837,1866,1867,1868],{"nctId":1870,"briefTitle":1871,"status":131,"phases":2208,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":104,"conditions":2209,"interventions":2210},[85],[34],[1837,1866,1867,1868],{"trials":2212,"activeCount":94},[],{"trials":2214,"activeCount":94},[],{"intervention":2216,"totalTrials":205,"cells":2217},"Onercept",{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2236,"NA":2238},{"trials":2219,"activeCount":94},[],{"trials":2221,"activeCount":94},[],{"trials":2223,"activeCount":94},[],{"trials":2225,"activeCount":94},[2226],{"nctId":2227,"briefTitle":2228,"status":131,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2235},"NCT00090129","Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis",[85],"2005-06","2004-09",854,[2234],"Arthritis, Psoriatic",[2216],{"trials":2237,"activeCount":94},[],{"trials":2239,"activeCount":94},[],{"intervention":2241,"totalTrials":205,"cells":2242},"New Formulation of rebif - human interferon beta-1a",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2261,"NA":2263},{"trials":2244,"activeCount":94},[],{"trials":2246,"activeCount":94},[],{"trials":2248,"activeCount":94},[],{"trials":2250,"activeCount":94},[2251],{"nctId":2252,"briefTitle":2253,"status":100,"phases":2254,"primaryCompletion":2255,"completion":1455,"start":1465,"enrollment":2256,"conditions":2257,"interventions":2259},"NCT00428584","RNF and Betaseron® Tolerability Study",[85],"2007-11",129,[2258],"Relapsing Remitting Multiple Sclerosis (RRMS)",[2241,2260],"Interferon beta -1b",{"trials":2262,"activeCount":94},[],{"trials":2264,"activeCount":94},[],{"intervention":2260,"totalTrials":205,"cells":2266},{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2279,"NA":2281},{"trials":2268,"activeCount":94},[],{"trials":2270,"activeCount":94},[],{"trials":2272,"activeCount":94},[],{"trials":2274,"activeCount":94},[2275],{"nctId":2252,"briefTitle":2253,"status":100,"phases":2276,"primaryCompletion":2255,"completion":1455,"start":1465,"enrollment":2256,"conditions":2277,"interventions":2278},[85],[2258],[2241,2260],{"trials":2280,"activeCount":94},[],{"trials":2282,"activeCount":94},[],{"intervention":2284,"totalTrials":205,"cells":2285},"Interferon-beta-1a FBS-free\u002FHSA-free",{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2290,"PHASE3":2292,"PHASE4":2303,"NA":2305},{"trials":2287,"activeCount":94},[],{"trials":2289,"activeCount":94},[],{"trials":2291,"activeCount":94},[],{"trials":2293,"activeCount":94},[2294],{"nctId":2295,"briefTitle":2296,"status":100,"phases":2297,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":2300,"conditions":2301,"interventions":2302},"NCT00110396","Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis",[85],"2007-04","2005-01",260,[15],[2284],{"trials":2304,"activeCount":94},[],{"trials":2306,"activeCount":94},[],{"intervention":2308,"totalTrials":205,"cells":2309},"Rebif® new formulation",{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2316,"PHASE4":2329,"NA":2331},{"trials":2311,"activeCount":94},[],{"trials":2313,"activeCount":94},[],{"trials":2315,"activeCount":94},[],{"trials":2317,"activeCount":94},[2318],{"nctId":2319,"briefTitle":2320,"status":100,"phases":2321,"primaryCompletion":2322,"completion":2323,"start":2324,"enrollment":2325,"conditions":2326,"interventions":2327},"NCT00725985","Oral Cladribine in Early Multiple Sclerosis (MS)",[85],"2011-07-31","2012-04-30","2008-12-31",617,[15],[2328,2308],"Cladribine",{"trials":2330,"activeCount":94},[],{"trials":2332,"activeCount":94},[],{"intervention":2334,"totalTrials":205,"cells":2335},"Recombinant Human-Luteinizing Hormone",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2354,"NA":2356},{"trials":2337,"activeCount":94},[],{"trials":2339,"activeCount":94},[],{"trials":2341,"activeCount":94},[],{"trials":2343,"activeCount":94},[2344],{"nctId":2345,"briefTitle":2346,"status":100,"phases":2347,"primaryCompletion":2348,"start":2231,"enrollment":2349,"conditions":2350,"interventions":2353},"NCT01121991","A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies",[85],"2005-09",55,[2351,2352],"Infertility","Ovarian Stimulation",[2334],{"trials":2355,"activeCount":94},[],{"trials":2357,"activeCount":94},[],{"intervention":2359,"totalTrials":205,"cells":2360},"Saizen®",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2379,"NA":2381},{"trials":2362,"activeCount":94},[],{"trials":2364,"activeCount":94},[],{"trials":2366,"activeCount":94},[],{"trials":2368,"activeCount":94},[2369],{"nctId":2370,"briefTitle":2371,"status":131,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2378},"NCT01237340","Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study",[85],"2011-12","2010-10",59,[2377],"Growth Hormone Deficiency (GHD)",[2359],{"trials":2380,"activeCount":94},[],{"trials":2382,"activeCount":94},[],{"intervention":1913,"totalTrials":205,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2397,"NA":2399},{"trials":2386,"activeCount":94},[],{"trials":2388,"activeCount":94},[],{"trials":2390,"activeCount":94},[],{"trials":2392,"activeCount":94},[2393],{"nctId":1905,"briefTitle":1906,"status":131,"phases":2394,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":1910,"conditions":2395,"interventions":2396},[85],[217],[1882,1901,1913],{"trials":2398,"activeCount":94},[],{"trials":2400,"activeCount":94},[],{"intervention":2402,"totalTrials":205,"cells":2403},"Serostim",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2422,"NA":2424},{"trials":2405,"activeCount":94},[],{"trials":2407,"activeCount":94},[],{"trials":2409,"activeCount":94},[],{"trials":2411,"activeCount":94},[2412],{"nctId":2413,"briefTitle":2414,"status":100,"phases":2415,"primaryCompletion":2416,"completion":2416,"start":2417,"enrollment":2418,"conditions":2419,"interventions":2421},"NCT01077960","Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome",[85],"2006-01","2005-02",126,[2420],"Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome",[2402],{"trials":2423,"activeCount":94},[],{"trials":2425,"activeCount":94},[],{"intervention":2427,"totalTrials":205,"cells":2428},"Interferon-beta-1a",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2448,"NA":2450},{"trials":2430,"activeCount":94},[],{"trials":2432,"activeCount":94},[],{"trials":2434,"activeCount":94},[],{"trials":2436,"activeCount":94},[2437],{"nctId":2438,"briefTitle":2439,"status":100,"phases":2440,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2446},"NCT00249860","A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects",[85],"2005-08","2002-09",257,[2445],"Hepatitis C",[2427,2447],"Ribavirin plus Interferon-beta-1a",{"trials":2449,"activeCount":94},[],{"trials":2451,"activeCount":94},[],{"intervention":2447,"totalTrials":205,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":94},[],{"trials":2457,"activeCount":94},[],{"trials":2459,"activeCount":94},[],{"trials":2461,"activeCount":94},[2462],{"nctId":2438,"briefTitle":2439,"status":100,"phases":2463,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2464,"interventions":2465},[85],[2445],[2427,2447],{"trials":2467,"activeCount":94},[],{"trials":2469,"activeCount":94},[],{"intervention":2471,"totalTrials":205,"cells":2472},"Cladribine 5.25 mg\u002Fkg",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2491,"NA":2493},{"trials":2474,"activeCount":94},[],{"trials":2476,"activeCount":94},[],{"trials":2478,"activeCount":94},[],{"trials":2480,"activeCount":94},[2481],{"nctId":2482,"briefTitle":2483,"status":100,"phases":2484,"primaryCompletion":2485,"completion":2485,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2489},"NCT00213135","A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)",[85],"2008-11","2005-04",1326,[2017],[2471,2490],"Cladribine 3.5 mg\u002Fkg",{"trials":2492,"activeCount":94},[],{"trials":2494,"activeCount":94},[],{"intervention":2490,"totalTrials":205,"cells":2496},{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2509,"NA":2511},{"trials":2498,"activeCount":94},[],{"trials":2500,"activeCount":94},[],{"trials":2502,"activeCount":94},[],{"trials":2504,"activeCount":94},[2505],{"nctId":2482,"briefTitle":2483,"status":100,"phases":2506,"primaryCompletion":2485,"completion":2485,"start":2486,"enrollment":2487,"conditions":2507,"interventions":2508},[85],[2017],[2471,2490],{"trials":2510,"activeCount":94},[],{"trials":2512,"activeCount":94},[],{"intervention":1499,"totalTrials":205,"cells":2514},{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2521,"PHASE4":2527,"NA":2529},{"trials":2516,"activeCount":94},[],{"trials":2518,"activeCount":94},[],{"trials":2520,"activeCount":94},[],{"trials":2522,"activeCount":94},[2523],{"nctId":1492,"briefTitle":1493,"status":131,"phases":2524,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":25,"conditions":2525,"interventions":2526},[84,85],[1437],[1423,1499,1500],{"trials":2528,"activeCount":94},[],{"trials":2530,"activeCount":94},[],{"intervention":1500,"totalTrials":205,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2545,"NA":2547},{"trials":2534,"activeCount":94},[],{"trials":2536,"activeCount":94},[],{"trials":2538,"activeCount":94},[],{"trials":2540,"activeCount":94},[2541],{"nctId":1492,"briefTitle":1493,"status":131,"phases":2542,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":25,"conditions":2543,"interventions":2544},[84,85],[1437],[1423,1499,1500],{"trials":2546,"activeCount":94},[],{"trials":2548,"activeCount":94},[],{"intervention":1953,"totalTrials":205,"cells":2550},{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2555,"PHASE3":2557,"PHASE4":2563,"NA":2565},{"trials":2552,"activeCount":94},[],{"trials":2554,"activeCount":94},[],{"trials":2556,"activeCount":94},[],{"trials":2558,"activeCount":94},[2559],{"nctId":1947,"briefTitle":1948,"status":131,"phases":2560,"primaryCompletion":1950,"completion":1950,"start":1455,"enrollment":1788,"conditions":2561,"interventions":2562},[85],[546],[1953,1954,1955],{"trials":2564,"activeCount":94},[],{"trials":2566,"activeCount":94},[],{"intervention":1955,"totalTrials":205,"cells":2568},{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2581,"NA":2583},{"trials":2570,"activeCount":94},[],{"trials":2572,"activeCount":94},[],{"trials":2574,"activeCount":94},[],{"trials":2576,"activeCount":94},[2577],{"nctId":1947,"briefTitle":1948,"status":131,"phases":2578,"primaryCompletion":1950,"completion":1950,"start":1455,"enrollment":1788,"conditions":2579,"interventions":2580},[85],[546],[1953,1954,1955],{"trials":2582,"activeCount":94},[],{"trials":2584,"activeCount":94},[],{"intervention":2586,"totalTrials":205,"cells":2587},"Serostim® 4 mg",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2608,"NA":2610},{"trials":2589,"activeCount":94},[],{"trials":2591,"activeCount":94},[],{"trials":2593,"activeCount":94},[],{"trials":2595,"activeCount":94},[2596],{"nctId":2597,"briefTitle":2598,"status":100,"phases":2599,"primaryCompletion":2600,"completion":2600,"start":2601,"enrollment":2602,"conditions":2603,"interventions":2606},"NCT00082628","Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients",[85],"2005-09-28","2004-05-28",326,[2604,2605],"HIV Infections","Lipodystrophy",[2586,2607],"Serostim® 2 mg",{"trials":2609,"activeCount":94},[],{"trials":2611,"activeCount":94},[],{"intervention":2607,"totalTrials":205,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":94},[],{"trials":2617,"activeCount":94},[],{"trials":2619,"activeCount":94},[],{"trials":2621,"activeCount":94},[2622],{"nctId":2597,"briefTitle":2598,"status":100,"phases":2623,"primaryCompletion":2600,"completion":2600,"start":2601,"enrollment":2602,"conditions":2624,"interventions":2625},[85],[2604,2605],[2586,2607],{"trials":2627,"activeCount":94},[],{"trials":2629,"activeCount":94},[],{"intervention":2631,"totalTrials":205,"cells":2632},"Rebif New Formulation Non Titrated",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2651,"NA":2653},{"trials":2634,"activeCount":94},[],{"trials":2636,"activeCount":94},[],{"trials":2638,"activeCount":94},[],{"trials":2640,"activeCount":94},[2641],{"nctId":2642,"briefTitle":2643,"status":100,"phases":2644,"primaryCompletion":2645,"completion":2646,"start":2298,"enrollment":2647,"conditions":2648,"interventions":2649},"NCT00472797","Rebif New Formulation (RNF) Quality of Life (QOL) Study",[85],"2009-02","2009-11",232,[1459],[2631,2650],"Rebif New Formulation Titrated",{"trials":2652,"activeCount":94},[],{"trials":2654,"activeCount":94},[],{"intervention":2650,"totalTrials":205,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":94},[],{"trials":2660,"activeCount":94},[],{"trials":2662,"activeCount":94},[],{"trials":2664,"activeCount":94},[2665],{"nctId":2642,"briefTitle":2643,"status":100,"phases":2666,"primaryCompletion":2645,"completion":2646,"start":2298,"enrollment":2647,"conditions":2667,"interventions":2668},[85],[1459],[2631,2650],{"trials":2670,"activeCount":94},[],{"trials":2672,"activeCount":94},[],{"intervention":1923,"totalTrials":205,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2687,"NA":2689},{"trials":2676,"activeCount":94},[],{"trials":2678,"activeCount":94},[],{"trials":2680,"activeCount":94},[],{"trials":2682,"activeCount":94},[2683],{"nctId":1915,"briefTitle":1916,"status":100,"phases":2684,"primaryCompletion":1765,"completion":1918,"start":1919,"enrollment":1920,"conditions":2685,"interventions":2686},[85],[512],[1882,1923],{"trials":2688,"activeCount":94},[],{"trials":2690,"activeCount":94},[],{"intervention":2692,"totalTrials":205,"cells":2693},"recombinant human growth hormone",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2700,"PHASE4":2713,"NA":2715},{"trials":2695,"activeCount":94},[],{"trials":2697,"activeCount":94},[],{"trials":2699,"activeCount":94},[],{"trials":2701,"activeCount":94},[2702],{"nctId":2703,"briefTitle":2704,"status":100,"phases":2705,"primaryCompletion":2706,"completion":2707,"start":2299,"enrollment":2708,"conditions":2709,"interventions":2712},"NCT00109733","Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency",[85],"2006-06","2006-07",31,[2710,2711],"Childhood-onset Growth Hormone Deficiency","Pituitary Dwarfism",[2692,2692],{"trials":2714,"activeCount":94},[],{"trials":2716,"activeCount":94},[],{"intervention":254,"totalTrials":205,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2725,"PHASE4":2731,"NA":2733},{"trials":2720,"activeCount":94},[],{"trials":2722,"activeCount":94},[],{"trials":2724,"activeCount":94},[],{"trials":2726,"activeCount":94},[2727],{"nctId":241,"briefTitle":242,"status":100,"phases":2728,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":2729,"interventions":2730},[85],[249],[49,251,239,252,252,108,253,108,254],{"trials":2732,"activeCount":94},[],{"trials":2734,"activeCount":94},[],{"intervention":266,"totalTrials":205,"cells":2736},{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2743,"PHASE4":2749,"NA":2751},{"trials":2738,"activeCount":94},[],{"trials":2740,"activeCount":94},[],{"trials":2742,"activeCount":94},[],{"trials":2744,"activeCount":94},[2745],{"nctId":256,"briefTitle":257,"status":100,"phases":2746,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":2747,"interventions":2748},[85],[264],[49,266,267,268,269,266,267,268,269],{"trials":2750,"activeCount":94},[],{"trials":2752,"activeCount":94},[],{"intervention":268,"totalTrials":205,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2761,"PHASE4":2767,"NA":2769},{"trials":2756,"activeCount":94},[],{"trials":2758,"activeCount":94},[],{"trials":2760,"activeCount":94},[],{"trials":2762,"activeCount":94},[2763],{"nctId":256,"briefTitle":257,"status":100,"phases":2764,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":2765,"interventions":2766},[85],[264],[49,266,267,268,269,266,267,268,269],{"trials":2768,"activeCount":94},[],{"trials":2770,"activeCount":94},[],{"intervention":2772,"totalTrials":205,"cells":2773},"Somatropin; Recombinant human growth hormone",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2791,"NA":2793},{"trials":2775,"activeCount":94},[],{"trials":2777,"activeCount":94},[],{"trials":2779,"activeCount":94},[],{"trials":2781,"activeCount":94},[2782],{"nctId":2783,"briefTitle":2784,"status":100,"phases":2785,"completion":2786,"start":2787,"conditions":2788,"interventions":2790},"NCT00489528","Growth Hormone in the Treatment of HIV-Associated Wasting",[85],"2002-03","1997-07",[2604,2789],"HIV Wasting Syndrome",[2772],{"trials":2792,"activeCount":94},[],{"trials":2794,"activeCount":94},[],{"intervention":2796,"totalTrials":205,"cells":2797},"Rebif® New Formulation (RNF) using RebiSmartTM",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2815,"NA":2817},{"trials":2799,"activeCount":94},[],{"trials":2801,"activeCount":94},[],{"trials":2803,"activeCount":94},[],{"trials":2805,"activeCount":94},[2806],{"nctId":2807,"briefTitle":2808,"status":100,"phases":2809,"primaryCompletion":2810,"start":2811,"enrollment":2812,"conditions":2813,"interventions":2814},"NCT00735007","12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.",[85],"2009-01","2008-07",106,[15],[2796],{"trials":2816,"activeCount":94},[],{"trials":2818,"activeCount":94},[],{"intervention":1576,"totalTrials":25,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2845,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2822,"activeCount":94},[],{"trials":2824,"activeCount":94},[2825,2835],{"nctId":2826,"briefTitle":2827,"status":131,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":2832,"interventions":2833},"NCT01378377","Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus",[83],"2012-02-23","2011-05-27",33,[18],[1576,1576,2834,2834],"Temsirolimus",{"nctId":2836,"briefTitle":2837,"status":100,"phases":2838,"primaryCompletion":2839,"completion":2840,"start":2841,"enrollment":1041,"conditions":2842,"interventions":2844},"NCT01992874","Relative Bioavailability of Pimasertib in Cancer Patients",[83],"2014-05-31","2015-02-28","2013-11-30",[2843],"Neoplasms",[1576,1576,1576,1576,1576],{"trials":2846,"activeCount":94},[2847,2855,2866,2878],{"nctId":2848,"briefTitle":2849,"status":131,"phases":2850,"primaryCompletion":1765,"completion":1765,"start":2851,"enrollment":1788,"conditions":2852,"interventions":2853},"NCT01085331","MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)",[83,84],"2010-03",[325],[1576,2854],"FOLFIRI",{"nctId":2856,"briefTitle":2857,"status":131,"phases":2858,"primaryCompletion":2859,"completion":2859,"start":2860,"enrollment":2861,"conditions":2862,"interventions":2865},"NCT00957580","Trial of Pimasertib in Hematological Malignancies",[84],"2012-12-31","2009-09-30",81,[2863,2864],"Leukemia, Myeloid, Acute","Hematologic Neoplasms",[1576,1576,1576,1576,1576],{"nctId":2867,"briefTitle":2868,"status":100,"phases":2869,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":2874,"interventions":2876},"NCT01693068","Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma",[84],"2015-07-04","2016-10-24","2012-12-05",194,[2875],"N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma",[1576,2877],"Dacarbazine",{"nctId":1567,"briefTitle":1568,"status":100,"phases":2879,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":440,"conditions":2880,"interventions":2881},[83,84],[1574],[1576,252],{"trials":2883,"activeCount":94},[],{"trials":2885,"activeCount":94},[],{"trials":2887,"activeCount":94},[],{"intervention":846,"totalTrials":30,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2906,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2891,"activeCount":94},[],{"trials":2893,"activeCount":94},[2894,2898,2902],{"nctId":1254,"briefTitle":1255,"status":100,"phases":2895,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":2896,"interventions":2897},[83],[18],[107,252,253,846,108,238],{"nctId":840,"briefTitle":841,"status":176,"phases":2899,"primaryCompletion":843,"completion":843,"start":843,"enrollment":94,"conditions":2900,"interventions":2901},[83],[27],[310,108,846,847,848,848,108],{"nctId":1290,"briefTitle":1291,"status":131,"phases":2903,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":170,"conditions":2904,"interventions":2905},[83],[1296],[161,253,846],{"trials":2907,"activeCount":94},[2908],{"nctId":1311,"briefTitle":1312,"status":131,"phases":2909,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":2910,"interventions":2911},[84],[512],[292,1319,846,251,108,239,253],{"trials":2913,"activeCount":94},[],{"trials":2915,"activeCount":94},[],{"trials":2917,"activeCount":94},[],{"intervention":496,"totalTrials":104,"cells":2919},{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2933,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2921,"activeCount":94},[],{"trials":2923,"activeCount":94},[2924],{"nctId":2925,"briefTitle":2926,"status":131,"phases":2927,"primaryCompletion":2928,"completion":2929,"start":2810,"enrollment":145,"conditions":2930,"interventions":2931},"NCT00719199","Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer",[83],"2011-04","2011-08",[32],[2932,496,2854],"IMO-2055",{"trials":2934,"activeCount":94},[2935,2939],{"nctId":487,"briefTitle":488,"status":131,"phases":2936,"primaryCompletion":490,"completion":491,"start":492,"enrollment":104,"conditions":2937,"interventions":2938},[84],[494],[40,496],{"nctId":2940,"briefTitle":2941,"status":100,"phases":2942,"primaryCompletion":2943,"start":2944,"enrollment":2945,"conditions":2946,"interventions":2948},"NCT01040832","EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[84],"2012-01","2009-12",107,[2947],"Squamous Cell Carcinoma of the Head and Neck Cancer",[496,2949],"EMD 1201081",{"trials":2951,"activeCount":94},[],{"trials":2953,"activeCount":94},[],{"trials":2955,"activeCount":94},[],{"intervention":2957,"totalTrials":170,"cells":2958},"M2951",{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2960,"activeCount":94},[],{"trials":2962,"activeCount":94},[],{"trials":2964,"activeCount":94},[2965,2975],{"nctId":2966,"briefTitle":2967,"status":100,"phases":2968,"primaryCompletion":2969,"completion":2970,"start":2971,"enrollment":2972,"conditions":2973,"interventions":2974},"NCT02784106","Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis",[84],"2017-04-30","2017-11-14","2016-07-31",65,[29],[2957,2957],{"nctId":2976,"briefTitle":2977,"status":131,"phases":2978,"primaryCompletion":2979,"completion":2980,"start":2981,"enrollment":2982,"conditions":2983,"interventions":2984},"NCT02975336","A Phase II Study of M2951 in SLE",[84],"2019-11-27","2020-03-23","2017-01-04",469,[1449],[2957,2957,2957,2957],{"trials":2986,"activeCount":94},[],{"trials":2988,"activeCount":94},[],{"trials":2990,"activeCount":94},[],{"intervention":2992,"totalTrials":170,"cells":2993},"Tucotuzumab celmoleukin",{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":3008,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":2995,"activeCount":94},[],{"trials":2997,"activeCount":94},[2998],{"nctId":2999,"briefTitle":3000,"status":100,"phases":3001,"start":3002,"conditions":3003,"interventions":3006},"NCT00016237","Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment",[83],"2000-12",[3004,3005,1638],"Bladder Cancer","Kidney Cancer",[3007],"tucotuzumab celmoleukin",{"trials":3009,"activeCount":94},[3010],{"nctId":3011,"briefTitle":3012,"status":176,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":94,"conditions":3016,"interventions":3017},"NCT00408967","Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.",[84],"2008-05-31","2006-12-31",[24],[2992],{"trials":3019,"activeCount":94},[],{"trials":3021,"activeCount":94},[],{"trials":3023,"activeCount":94},[],{"intervention":3025,"totalTrials":170,"cells":3026},"SAR245409",{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3043,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3028,"activeCount":94},[],{"trials":3030,"activeCount":94},[3031],{"nctId":3032,"briefTitle":3033,"status":100,"phases":3034,"primaryCompletion":1918,"completion":1918,"start":3035,"enrollment":1614,"conditions":3036,"interventions":3041},"NCT01390818","Trial of MEK Inhibitor and PI3K\u002FmTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",[83],"2011-05",[3037,3038,546,3039,3040,32],"Locally Advanced Solid Tumor","Metastatic Solid Tumor","Non Small Cell Lung Cancer","Melanoma",[3042,3025,3042,3025],"MSC1936369B",{"trials":3044,"activeCount":94},[3045],{"nctId":3046,"briefTitle":3047,"status":100,"phases":3048,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":2972,"conditions":3052,"interventions":3053},"NCT01936363","Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer",[84],"2015-05-31","2017-11-30","2013-09-30",[24],[3054,3055,3056,3025,3057],"Pimasertib once daily","Pimasertib placebo","SAR245409 placebo","Pimasertib twice daily",{"trials":3059,"activeCount":94},[],{"trials":3061,"activeCount":94},[],{"trials":3063,"activeCount":94},[],{"intervention":2854,"totalTrials":170,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3074,"PHASE3":3080,"PHASE4":3082,"NA":3084},{"trials":3067,"activeCount":94},[],{"trials":3069,"activeCount":94},[3070],{"nctId":2925,"briefTitle":2926,"status":131,"phases":3071,"primaryCompletion":2928,"completion":2929,"start":2810,"enrollment":145,"conditions":3072,"interventions":3073},[83],[32],[2932,496,2854],{"trials":3075,"activeCount":94},[3076],{"nctId":2848,"briefTitle":2849,"status":131,"phases":3077,"primaryCompletion":1765,"completion":1765,"start":2851,"enrollment":1788,"conditions":3078,"interventions":3079},[83,84],[325],[1576,2854],{"trials":3081,"activeCount":94},[],{"trials":3083,"activeCount":94},[],{"trials":3085,"activeCount":94},[],{"intervention":1747,"totalTrials":170,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3102,"PHASE4":3104,"NA":3106},{"trials":3089,"activeCount":94},[],{"trials":3091,"activeCount":94},[],{"trials":3093,"activeCount":94},[3094,3098],{"nctId":1784,"briefTitle":1785,"status":131,"phases":3095,"primaryCompletion":1787,"completion":1787,"start":134,"enrollment":1788,"conditions":3096,"interventions":3097},[84],[1790],[1747,1748],{"nctId":1739,"briefTitle":1740,"status":131,"phases":3099,"primaryCompletion":1455,"completion":1742,"start":1743,"enrollment":1744,"conditions":3100,"interventions":3101},[84],[1459],[1747,1748,1718,1718],{"trials":3103,"activeCount":94},[],{"trials":3105,"activeCount":94},[],{"trials":3107,"activeCount":94},[],{"intervention":3109,"totalTrials":170,"cells":3110},"Sprifermin",{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3112,"activeCount":94},[],{"trials":3114,"activeCount":94},[],{"trials":3116,"activeCount":94},[3117,3126],{"nctId":3118,"briefTitle":3119,"status":131,"phases":3120,"primaryCompletion":3121,"completion":3121,"start":3122,"enrollment":205,"conditions":3123,"interventions":3125},"NCT01689337","A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee",[84],"2013-10","2013-04",[3124],"Cartilage Injury of Knee",[3109,3109],{"nctId":3127,"briefTitle":3128,"status":100,"phases":3129,"primaryCompletion":3130,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3136},"NCT01919164","A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee",[84],"2016-05-05","2019-05-07","2013-07-29",549,[3135],"Osteoarthritis, Knee",[3109],{"trials":3138,"activeCount":94},[],{"trials":3140,"activeCount":94},[],{"trials":3142,"activeCount":94},[],{"intervention":3144,"totalTrials":205,"cells":3145},"Plovamer acetate 0.5 milligram",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3147,"activeCount":94},[],{"trials":3149,"activeCount":94},[],{"trials":3151,"activeCount":94},[3152],{"nctId":3153,"briefTitle":3154,"status":131,"phases":3155,"primaryCompletion":3156,"completion":3156,"start":3121,"enrollment":1457,"conditions":3157,"interventions":3159},"NCT01963611","Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",[84],"2015-03",[3158],"Relapsing Remitting Multiple Sclerosis",[3144,3160,3161,3162,3163],"Copaxone 20 mg","Plovamer acetate 3 mg","Plovamer acetate 10 mg","Plovamer acetate 20 mg",{"trials":3165,"activeCount":94},[],{"trials":3167,"activeCount":94},[],{"trials":3169,"activeCount":94},[],{"intervention":3160,"totalTrials":205,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":94},[],{"trials":3175,"activeCount":94},[],{"trials":3177,"activeCount":94},[3178],{"nctId":3153,"briefTitle":3154,"status":131,"phases":3179,"primaryCompletion":3156,"completion":3156,"start":3121,"enrollment":1457,"conditions":3180,"interventions":3181},[84],[3158],[3144,3160,3161,3162,3163],{"trials":3183,"activeCount":94},[],{"trials":3185,"activeCount":94},[],{"trials":3187,"activeCount":94},[],{"intervention":3161,"totalTrials":205,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3200,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":94},[],{"trials":3193,"activeCount":94},[],{"trials":3195,"activeCount":94},[3196],{"nctId":3153,"briefTitle":3154,"status":131,"phases":3197,"primaryCompletion":3156,"completion":3156,"start":3121,"enrollment":1457,"conditions":3198,"interventions":3199},[84],[3158],[3144,3160,3161,3162,3163],{"trials":3201,"activeCount":94},[],{"trials":3203,"activeCount":94},[],{"trials":3205,"activeCount":94},[],{"intervention":3162,"totalTrials":205,"cells":3207},{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3218,"PHASE4":3220,"NA":3222},{"trials":3209,"activeCount":94},[],{"trials":3211,"activeCount":94},[],{"trials":3213,"activeCount":94},[3214],{"nctId":3153,"briefTitle":3154,"status":131,"phases":3215,"primaryCompletion":3156,"completion":3156,"start":3121,"enrollment":1457,"conditions":3216,"interventions":3217},[84],[3158],[3144,3160,3161,3162,3163],{"trials":3219,"activeCount":94},[],{"trials":3221,"activeCount":94},[],{"trials":3223,"activeCount":94},[],{"intervention":3163,"totalTrials":205,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3236,"PHASE4":3238,"NA":3240},{"trials":3227,"activeCount":94},[],{"trials":3229,"activeCount":94},[],{"trials":3231,"activeCount":94},[3232],{"nctId":3153,"briefTitle":3154,"status":131,"phases":3233,"primaryCompletion":3156,"completion":3156,"start":3121,"enrollment":1457,"conditions":3234,"interventions":3235},[84],[3158],[3144,3160,3161,3162,3163],{"trials":3237,"activeCount":94},[],{"trials":3239,"activeCount":94},[],{"trials":3241,"activeCount":94},[],{"intervention":3243,"totalTrials":205,"cells":3244},"Anastrozole 1 mg",{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3265,"PHASE4":3267,"NA":3269},{"trials":3246,"activeCount":94},[],{"trials":3248,"activeCount":94},[],{"trials":3250,"activeCount":94},[3251],{"nctId":3252,"briefTitle":3253,"status":100,"phases":3254,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3258,"interventions":3260},"NCT00213148","Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction",[84],"2007-12-12","2005-03-10",271,[3259],"Anovulation",[3243,3261,3262,3263,3264],"Anastrozole 5 mg","Anastrozole 10 mg","Clomiphene Citrate 50 mg","Clomiphene Citrate 100 mg",{"trials":3266,"activeCount":94},[],{"trials":3268,"activeCount":94},[],{"trials":3270,"activeCount":94},[],{"intervention":3261,"totalTrials":205,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3274,"activeCount":94},[],{"trials":3276,"activeCount":94},[],{"trials":3278,"activeCount":94},[3279],{"nctId":3252,"briefTitle":3253,"status":100,"phases":3280,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3281,"interventions":3282},[84],[3259],[3243,3261,3262,3263,3264],{"trials":3284,"activeCount":94},[],{"trials":3286,"activeCount":94},[],{"trials":3288,"activeCount":94},[],{"intervention":3262,"totalTrials":205,"cells":3290},{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3292,"activeCount":94},[],{"trials":3294,"activeCount":94},[],{"trials":3296,"activeCount":94},[3297],{"nctId":3252,"briefTitle":3253,"status":100,"phases":3298,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3299,"interventions":3300},[84],[3259],[3243,3261,3262,3263,3264],{"trials":3302,"activeCount":94},[],{"trials":3304,"activeCount":94},[],{"trials":3306,"activeCount":94},[],{"intervention":3263,"totalTrials":205,"cells":3308},{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3310,"activeCount":94},[],{"trials":3312,"activeCount":94},[],{"trials":3314,"activeCount":94},[3315],{"nctId":3252,"briefTitle":3253,"status":100,"phases":3316,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3317,"interventions":3318},[84],[3259],[3243,3261,3262,3263,3264],{"trials":3320,"activeCount":94},[],{"trials":3322,"activeCount":94},[],{"trials":3324,"activeCount":94},[],{"intervention":3264,"totalTrials":205,"cells":3326},{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3328,"activeCount":94},[],{"trials":3330,"activeCount":94},[],{"trials":3332,"activeCount":94},[3333],{"nctId":3252,"briefTitle":3253,"status":100,"phases":3334,"primaryCompletion":3255,"completion":3255,"start":3256,"enrollment":3257,"conditions":3335,"interventions":3336},[84],[3259],[3243,3261,3262,3263,3264],{"trials":3338,"activeCount":94},[],{"trials":3340,"activeCount":94},[],{"trials":3342,"activeCount":94},[],{"intervention":3054,"totalTrials":205,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3346,"activeCount":94},[],{"trials":3348,"activeCount":94},[],{"trials":3350,"activeCount":94},[3351],{"nctId":3046,"briefTitle":3047,"status":100,"phases":3352,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":2972,"conditions":3353,"interventions":3354},[84],[24],[3054,3055,3056,3025,3057],{"trials":3356,"activeCount":94},[],{"trials":3358,"activeCount":94},[],{"trials":3360,"activeCount":94},[],{"intervention":3055,"totalTrials":205,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3364,"activeCount":94},[],{"trials":3366,"activeCount":94},[],{"trials":3368,"activeCount":94},[3369],{"nctId":3046,"briefTitle":3047,"status":100,"phases":3370,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":2972,"conditions":3371,"interventions":3372},[84],[24],[3054,3055,3056,3025,3057],{"trials":3374,"activeCount":94},[],{"trials":3376,"activeCount":94},[],{"trials":3378,"activeCount":94},[],{"intervention":3056,"totalTrials":205,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":94},[],{"trials":3384,"activeCount":94},[],{"trials":3386,"activeCount":94},[3387],{"nctId":3046,"briefTitle":3047,"status":100,"phases":3388,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":2972,"conditions":3389,"interventions":3390},[84],[24],[3054,3055,3056,3025,3057],{"trials":3392,"activeCount":94},[],{"trials":3394,"activeCount":94},[],{"trials":3396,"activeCount":94},[],{"intervention":3057,"totalTrials":205,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":94},[],{"trials":3402,"activeCount":94},[],{"trials":3404,"activeCount":94},[3405],{"nctId":3046,"briefTitle":3047,"status":100,"phases":3406,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":2972,"conditions":3407,"interventions":3408},[84],[24],[3054,3055,3056,3025,3057],{"trials":3410,"activeCount":94},[],{"trials":3412,"activeCount":94},[],{"trials":3414,"activeCount":94},[],{"intervention":3416,"totalTrials":205,"cells":3417},"M5049 high dose",{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3419,"activeCount":94},[],{"trials":3421,"activeCount":94},[],{"trials":3423,"activeCount":94},[3424],{"nctId":3425,"briefTitle":3426,"status":131,"phases":3427,"primaryCompletion":3428,"completion":3428,"start":3429,"enrollment":3430,"conditions":3431,"interventions":3434},"NCT05650567","Study of M5049 in DM and PM Participants (NEPTUNIA)",[84],"2025-06-25","2023-01-19",40,[3432,3433],"Dermatomyositis","Polymyositis",[3416],{"trials":3436,"activeCount":94},[],{"trials":3438,"activeCount":94},[],{"trials":3440,"activeCount":94},[],{"intervention":3442,"totalTrials":205,"cells":3443},"Interferon beta-1a",{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3445,"activeCount":94},[],{"trials":3447,"activeCount":94},[],{"trials":3449,"activeCount":94},[3450],{"nctId":3451,"briefTitle":3452,"status":131,"phases":3453,"completion":1072,"start":3454,"enrollment":3455,"conditions":3456,"interventions":3458},"NCT00304252","Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease",[84],"2001-11",192,[3457],"Crohn's Disease",[3442],{"trials":3460,"activeCount":94},[],{"trials":3462,"activeCount":94},[],{"trials":3464,"activeCount":94},[],{"intervention":1855,"totalTrials":205,"cells":3466},{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3468,"activeCount":94},[],{"trials":3470,"activeCount":94},[],{"trials":3472,"activeCount":94},[3473],{"nctId":1846,"briefTitle":1847,"status":131,"phases":3474,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":3475,"interventions":3476},[84],[34],[1837,1837,1837,1855],{"trials":3478,"activeCount":94},[],{"trials":3480,"activeCount":94},[],{"trials":3482,"activeCount":94},[],{"intervention":3484,"totalTrials":205,"cells":3485},"M5049",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3487,"activeCount":94},[],{"trials":3489,"activeCount":94},[],{"trials":3491,"activeCount":94},[3492],{"nctId":3493,"briefTitle":3494,"status":100,"phases":3495,"primaryCompletion":3496,"completion":3496,"start":3497,"enrollment":3498,"conditions":3499,"interventions":3501},"NCT04448756","Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)",[84],"2021-08-16","2020-07-29",149,[3500],"Coronavirus Disease 2019",[3484,3484],{"trials":3503,"activeCount":94},[],{"trials":3505,"activeCount":94},[],{"trials":3507,"activeCount":94},[],{"intervention":1309,"totalTrials":205,"cells":3509},{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3514,"PHASE3":3520,"PHASE4":3522,"NA":3524},{"trials":3511,"activeCount":94},[],{"trials":3513,"activeCount":94},[],{"trials":3515,"activeCount":94},[3516],{"nctId":1301,"briefTitle":1302,"status":100,"phases":3517,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":3518,"interventions":3519},[83,84],[217],[253,108,251,1309,252,219,292,108,108,650,239],{"trials":3521,"activeCount":94},[],{"trials":3523,"activeCount":94},[],{"trials":3525,"activeCount":94},[],{"intervention":1319,"totalTrials":205,"cells":3527},{"EARLY_PHASE1":3528,"PHASE1":3530,"PHASE2":3532,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3529,"activeCount":94},[],{"trials":3531,"activeCount":94},[],{"trials":3533,"activeCount":94},[3534],{"nctId":1311,"briefTitle":1312,"status":131,"phases":3535,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":3536,"interventions":3537},[84],[512],[292,1319,846,251,108,239,253],{"trials":3539,"activeCount":94},[],{"trials":3541,"activeCount":94},[],{"trials":3543,"activeCount":94},[],{"intervention":3545,"totalTrials":205,"cells":3546},"MSB0010445",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3548,"activeCount":94},[],{"trials":3550,"activeCount":94},[],{"trials":3552,"activeCount":94},[3553],{"nctId":3554,"briefTitle":3555,"status":131,"phases":3556,"primaryCompletion":1918,"completion":3557,"start":3558,"enrollment":3559,"conditions":3560,"interventions":3561},"NCT01973608","MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma",[84],"2015-06","2014-01",12,[3040],[3545,3545,3545,3545],{"trials":3563,"activeCount":94},[],{"trials":3565,"activeCount":94},[],{"trials":3567,"activeCount":94},[],{"intervention":1737,"totalTrials":205,"cells":3569},{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3574,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3571,"activeCount":94},[],{"trials":3573,"activeCount":94},[],{"trials":3575,"activeCount":94},[3576],{"nctId":1727,"briefTitle":1728,"status":100,"phases":3577,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":3578,"interventions":3579},[84],[1735],[1737,1718],{"trials":3581,"activeCount":94},[],{"trials":3583,"activeCount":94},[],{"trials":3585,"activeCount":94},[],{"intervention":2877,"totalTrials":205,"cells":3587},{"EARLY_PHASE1":3588,"PHASE1":3590,"PHASE2":3592,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3589,"activeCount":94},[],{"trials":3591,"activeCount":94},[],{"trials":3593,"activeCount":94},[3594],{"nctId":2867,"briefTitle":2868,"status":100,"phases":3595,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":3596,"interventions":3597},[84],[2875],[1576,2877],{"trials":3599,"activeCount":94},[],{"trials":3601,"activeCount":94},[],{"trials":3603,"activeCount":94},[],{"intervention":3605,"totalTrials":205,"cells":3606},"Interferon-beta",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3608,"activeCount":94},[],{"trials":3610,"activeCount":94},[],{"trials":3612,"activeCount":94},[3613],{"nctId":3614,"briefTitle":3615,"status":100,"phases":3616,"primaryCompletion":3617,"completion":1039,"start":3618,"enrollment":3619,"conditions":3620,"interventions":3621},"NCT00436826","A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)",[84],"2011-09-30","2006-11-30",172,[15],[2328,3605],{"trials":3623,"activeCount":94},[],{"trials":3625,"activeCount":94},[],{"trials":3627,"activeCount":94},[],{"intervention":3629,"totalTrials":205,"cells":3630},"Cilengitide 500 mg",{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3648,"PHASE4":3650,"NA":3652},{"trials":3632,"activeCount":94},[],{"trials":3634,"activeCount":94},[],{"trials":3636,"activeCount":94},[3637],{"nctId":3638,"briefTitle":3639,"status":100,"phases":3640,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":2861,"conditions":3644,"interventions":3646},"NCT00093964","Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)",[84],"2005-10-28","2010-10-21","2004-10-13",[3645],"Glioblastoma Multiforme",[3629,3647],"Cilengitide 2000 mg",{"trials":3649,"activeCount":94},[],{"trials":3651,"activeCount":94},[],{"trials":3653,"activeCount":94},[],{"intervention":3647,"totalTrials":205,"cells":3655},{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3657,"activeCount":94},[],{"trials":3659,"activeCount":94},[],{"trials":3661,"activeCount":94},[3662],{"nctId":3638,"briefTitle":3639,"status":100,"phases":3663,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":2861,"conditions":3664,"interventions":3665},[84],[3645],[3629,3647],{"trials":3667,"activeCount":94},[],{"trials":3669,"activeCount":94},[],{"trials":3671,"activeCount":94},[],{"intervention":3673,"totalTrials":205,"cells":3674},"M2591 25 mg QD",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3676,"activeCount":94},[],{"trials":3678,"activeCount":94},[],{"trials":3680,"activeCount":94},[3681],{"nctId":3682,"briefTitle":3683,"status":100,"phases":3684,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3689},"NCT03233230","Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis",[84],"2019-09-23","2017-09-18",390,[29],[3673,3690,3691],"M2951 75 mg QD","M2951 50 mg BID",{"trials":3693,"activeCount":94},[],{"trials":3695,"activeCount":94},[],{"trials":3697,"activeCount":94},[],{"intervention":3690,"totalTrials":205,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3704,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3701,"activeCount":94},[],{"trials":3703,"activeCount":94},[],{"trials":3705,"activeCount":94},[3706],{"nctId":3682,"briefTitle":3683,"status":100,"phases":3707,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":3708,"interventions":3709},[84],[29],[3673,3690,3691],{"trials":3711,"activeCount":94},[],{"trials":3713,"activeCount":94},[],{"trials":3715,"activeCount":94},[],{"intervention":3691,"totalTrials":205,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3719,"activeCount":94},[],{"trials":3721,"activeCount":94},[],{"trials":3723,"activeCount":94},[3724],{"nctId":3682,"briefTitle":3683,"status":100,"phases":3725,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":3726,"interventions":3727},[84],[29],[3673,3690,3691],{"trials":3729,"activeCount":94},[],{"trials":3731,"activeCount":94},[],{"trials":3733,"activeCount":94},[],{"intervention":757,"totalTrials":205,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":94},[],{"trials":3739,"activeCount":94},[],{"trials":3741,"activeCount":94},[3742],{"nctId":748,"briefTitle":749,"status":100,"phases":3743,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":3744,"interventions":3745},[83,84],[755],[757,758,759,760,269],{"trials":3747,"activeCount":94},[],{"trials":3749,"activeCount":94},[],{"trials":3751,"activeCount":94},[],{"intervention":758,"totalTrials":205,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3755,"activeCount":94},[],{"trials":3757,"activeCount":94},[],{"trials":3759,"activeCount":94},[3760],{"nctId":748,"briefTitle":749,"status":100,"phases":3761,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":3762,"interventions":3763},[83,84],[755],[757,758,759,760,269],{"trials":3765,"activeCount":94},[],{"trials":3767,"activeCount":94},[],{"trials":3769,"activeCount":94},[],{"intervention":759,"totalTrials":205,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3782,"PHASE4":3784,"NA":3786},{"trials":3773,"activeCount":94},[],{"trials":3775,"activeCount":94},[],{"trials":3777,"activeCount":94},[3778],{"nctId":748,"briefTitle":749,"status":100,"phases":3779,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":3780,"interventions":3781},[83,84],[755],[757,758,759,760,269],{"trials":3783,"activeCount":94},[],{"trials":3785,"activeCount":94},[],{"trials":3787,"activeCount":94},[],{"intervention":760,"totalTrials":205,"cells":3789},{"EARLY_PHASE1":3790,"PHASE1":3792,"PHASE2":3794,"PHASE3":3800,"PHASE4":3802,"NA":3804},{"trials":3791,"activeCount":94},[],{"trials":3793,"activeCount":94},[],{"trials":3795,"activeCount":94},[3796],{"nctId":748,"briefTitle":749,"status":100,"phases":3797,"primaryCompletion":751,"completion":752,"start":753,"enrollment":9,"conditions":3798,"interventions":3799},[83,84],[755],[757,758,759,760,269],{"trials":3801,"activeCount":94},[],{"trials":3803,"activeCount":94},[],{"trials":3805,"activeCount":94},[],{"intervention":3807,"totalTrials":205,"cells":3808},"Interferon-beta-1a, 44 microgram",{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3825,"PHASE4":3827,"NA":3829},{"trials":3810,"activeCount":94},[],{"trials":3812,"activeCount":94},[],{"trials":3814,"activeCount":94},[3815],{"nctId":3816,"briefTitle":3817,"status":100,"phases":3818,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":2873,"conditions":3821,"interventions":3823},"NCT00303381","Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis",[84],"2003-01","2001-12",[3822],"Ulcerative Colitis",[3807,3824],"Interferon-beta-1a, 66 microgram",{"trials":3826,"activeCount":94},[],{"trials":3828,"activeCount":94},[],{"trials":3830,"activeCount":94},[],{"intervention":3824,"totalTrials":205,"cells":3832},{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3834,"activeCount":94},[],{"trials":3836,"activeCount":94},[],{"trials":3838,"activeCount":94},[3839],{"nctId":3816,"briefTitle":3817,"status":100,"phases":3840,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":2873,"conditions":3841,"interventions":3842},[84],[3822],[3807,3824],{"trials":3844,"activeCount":94},[],{"trials":3846,"activeCount":94},[],{"trials":3848,"activeCount":94},[],{"intervention":3850,"totalTrials":205,"cells":3851},"Abituzumab 1500 mg",{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3869,"PHASE4":3871,"NA":3873},{"trials":3853,"activeCount":94},[],{"trials":3855,"activeCount":94},[],{"trials":3857,"activeCount":94},[3858],{"nctId":3859,"briefTitle":3860,"status":131,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":3864,"conditions":3865,"interventions":3867},"NCT02745145","Abituzumab in SSc-ILD",[84],"2018-05-30","2016-05-31",24,[3866],"Systemic Sclerosis-associated Interstitial Lung Disease",[3850,3868],"Abituzumab 500 mg",{"trials":3870,"activeCount":94},[],{"trials":3872,"activeCount":94},[],{"trials":3874,"activeCount":94},[],{"intervention":3868,"totalTrials":205,"cells":3876},{"EARLY_PHASE1":3877,"PHASE1":3879,"PHASE2":3881,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3878,"activeCount":94},[],{"trials":3880,"activeCount":94},[],{"trials":3882,"activeCount":94},[3883],{"nctId":3859,"briefTitle":3860,"status":131,"phases":3884,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":3864,"conditions":3885,"interventions":3886},[84],[3866],[3850,3868],{"trials":3888,"activeCount":94},[],{"trials":3890,"activeCount":94},[],{"trials":3892,"activeCount":94},[],{"intervention":3894,"totalTrials":205,"cells":3895},"Berzosertib",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3897,"activeCount":94},[],{"trials":3899,"activeCount":94},[],{"trials":3901,"activeCount":94},[3902],{"nctId":3903,"briefTitle":3904,"status":100,"phases":3905,"primaryCompletion":3906,"completion":3906,"start":3907,"enrollment":3908,"conditions":3909,"interventions":3911},"NCT04768296","Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)",[84],"2023-07-21","2021-03-29",76,[3910],"Small-cell Lung Cancer",[3894,3894,3912],"Topotecan",{"trials":3914,"activeCount":94},[],{"trials":3916,"activeCount":94},[],{"trials":3918,"activeCount":94},[],{"intervention":3912,"totalTrials":205,"cells":3920},{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3925,"PHASE3":3931,"PHASE4":3933,"NA":3935},{"trials":3922,"activeCount":94},[],{"trials":3924,"activeCount":94},[],{"trials":3926,"activeCount":94},[3927],{"nctId":3903,"briefTitle":3904,"status":100,"phases":3928,"primaryCompletion":3906,"completion":3906,"start":3907,"enrollment":3908,"conditions":3929,"interventions":3930},[84],[3910],[3894,3894,3912],{"trials":3932,"activeCount":94},[],{"trials":3934,"activeCount":94},[],{"trials":3936,"activeCount":94},[],{"intervention":3938,"totalTrials":205,"cells":3939},"EMD 525797",{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3944,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3941,"activeCount":94},[],{"trials":3943,"activeCount":94},[],{"trials":3945,"activeCount":94},[3946],{"nctId":3947,"briefTitle":3948,"status":100,"phases":3949,"primaryCompletion":3122,"completion":3950,"start":2928,"enrollment":3951,"conditions":3952,"interventions":3954},"NCT01360840","EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer",[84],"2014-07",180,[3953],"Prostate Cancer Metastatic",[3938,3938],{"trials":3956,"activeCount":94},[],{"trials":3958,"activeCount":94},[],{"trials":3960,"activeCount":94},[],{"intervention":3962,"totalTrials":205,"cells":3963},"Sarizotan HCl",{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3965,"activeCount":94},[],{"trials":3967,"activeCount":94},[],{"trials":3969,"activeCount":94},[3970],{"nctId":3971,"briefTitle":3972,"status":100,"phases":3973,"completion":3974,"start":3975,"enrollment":3976,"conditions":3977,"interventions":3978},"NCT00314288","Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia",[84],"2003-07","2002-07",360,[2042,2043],[3962],{"trials":3980,"activeCount":94},[],{"trials":3982,"activeCount":94},[],{"trials":3984,"activeCount":94},[],{"intervention":2949,"totalTrials":205,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3988,"activeCount":94},[],{"trials":3990,"activeCount":94},[],{"trials":3992,"activeCount":94},[3993],{"nctId":2940,"briefTitle":2941,"status":100,"phases":3994,"primaryCompletion":2943,"start":2944,"enrollment":2945,"conditions":3995,"interventions":3996},[84],[2947],[496,2949],{"trials":3998,"activeCount":94},[],{"trials":4000,"activeCount":94},[],{"trials":4002,"activeCount":94},[],{"intervention":4004,"totalTrials":205,"cells":4005},"ONO-4641",{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4007,"activeCount":94},[],{"trials":4009,"activeCount":94},[],{"trials":4011,"activeCount":94},[4012],{"nctId":4013,"briefTitle":4014,"status":131,"phases":4015,"primaryCompletion":4016,"completion":4016,"start":2374,"enrollment":4017,"conditions":4018,"interventions":4019},"NCT01226745","Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)",[84],"2015-01",340,[15],[4004,4004,4004,4004,4004,4004],{"trials":4021,"activeCount":94},[],{"trials":4023,"activeCount":94},[],{"trials":4025,"activeCount":94},[],{"intervention":548,"totalTrials":205,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4032,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4029,"activeCount":94},[],{"trials":4031,"activeCount":94},[],{"trials":4033,"activeCount":94},[4034],{"nctId":540,"briefTitle":541,"status":176,"phases":4035,"primaryCompletion":543,"completion":543,"start":544,"enrollment":94,"conditions":4036,"interventions":4037},[83,84],[18,546],[462,548,462,548,462,462],{"trials":4039,"activeCount":94},[],{"trials":4041,"activeCount":94},[],{"trials":4043,"activeCount":94},[],{"intervention":1706,"totalTrials":205,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4047,"activeCount":94},[],{"trials":4049,"activeCount":94},[],{"trials":4051,"activeCount":94},[4052],{"nctId":1696,"briefTitle":1697,"status":100,"phases":4053,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":4054,"interventions":4055},[84],[1638,1704],[251,1706],{"trials":4057,"activeCount":94},[],{"trials":4059,"activeCount":94},[],{"trials":4061,"activeCount":94},[],{"intervention":1900,"totalTrials":205,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4065,"activeCount":94},[],{"trials":4067,"activeCount":94},[],{"trials":4069,"activeCount":94},[4070],{"nctId":1891,"briefTitle":1892,"status":100,"phases":4071,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":4072,"interventions":4073},[84],[1898],[1900,1901,1882],{"trials":4075,"activeCount":94},[],{"trials":4077,"activeCount":94},[],{"trials":4079,"activeCount":94},[],{"intervention":1487,"totalTrials":205,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4083,"activeCount":94},[],{"trials":4085,"activeCount":94},[],{"trials":4087,"activeCount":94},[4088],{"nctId":1479,"briefTitle":1480,"status":100,"phases":4089,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":1484,"conditions":4090,"interventions":4091},[84],[29],[1487,1423,1488],{"trials":4093,"activeCount":94},[],{"trials":4095,"activeCount":94},[],{"trials":4097,"activeCount":94},[],{"intervention":1488,"totalTrials":205,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4101,"activeCount":94},[],{"trials":4103,"activeCount":94},[],{"trials":4105,"activeCount":94},[4106],{"nctId":1479,"briefTitle":1480,"status":100,"phases":4107,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":1484,"conditions":4108,"interventions":4109},[84],[29],[1487,1423,1488],{"trials":4111,"activeCount":94},[],{"trials":4113,"activeCount":94},[],{"trials":4115,"activeCount":94},[],{"intervention":4117,"totalTrials":205,"cells":4118},"Enpatoran low dose",{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4120,"activeCount":94},[],{"trials":4122,"activeCount":94},[],{"trials":4124,"activeCount":94},[4125],{"nctId":4126,"briefTitle":4127,"status":100,"phases":4128,"primaryCompletion":4129,"completion":4129,"start":491,"enrollment":4130,"conditions":4131,"interventions":4132},"NCT05162586","The WILLOW Study With M5049 in SLE and CLE (SCLE and\u002For DLE) (WILLOW)",[84],"2024-11-20",456,[1449],[4117,4133,4134],"Enpatoran medium dose","Enpatoran high dose",{"trials":4136,"activeCount":94},[],{"trials":4138,"activeCount":94},[],{"trials":4140,"activeCount":94},[],{"intervention":4133,"totalTrials":205,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4147,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4144,"activeCount":94},[],{"trials":4146,"activeCount":94},[],{"trials":4148,"activeCount":94},[4149],{"nctId":4126,"briefTitle":4127,"status":100,"phases":4150,"primaryCompletion":4129,"completion":4129,"start":491,"enrollment":4130,"conditions":4151,"interventions":4152},[84],[1449],[4117,4133,4134],{"trials":4154,"activeCount":94},[],{"trials":4156,"activeCount":94},[],{"trials":4158,"activeCount":94},[],{"intervention":4134,"totalTrials":205,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4162,"activeCount":94},[],{"trials":4164,"activeCount":94},[],{"trials":4166,"activeCount":94},[4167],{"nctId":4126,"briefTitle":4127,"status":100,"phases":4168,"primaryCompletion":4129,"completion":4129,"start":491,"enrollment":4130,"conditions":4169,"interventions":4170},[84],[1449],[4117,4133,4134],{"trials":4172,"activeCount":94},[],{"trials":4174,"activeCount":94},[],{"trials":4176,"activeCount":94},[],{"intervention":4178,"totalTrials":205,"cells":4179},"EMD 72000",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4181,"activeCount":94},[],{"trials":4183,"activeCount":94},[],{"trials":4185,"activeCount":94},[4186],{"nctId":4187,"briefTitle":4188,"status":100,"phases":4189,"primaryCompletion":4190,"completion":4191,"start":4192,"enrollment":1041,"conditions":4193,"interventions":4194},"NCT00073541","A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer",[84],"2004-03","2004-08","2003-04",[24],[4178],{"trials":4196,"activeCount":94},[],{"trials":4198,"activeCount":94},[],{"trials":4200,"activeCount":94},[],{"intervention":107,"totalTrials":170,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4215,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4204,"activeCount":94},[],{"trials":4206,"activeCount":94},[4207,4211],{"nctId":1254,"briefTitle":1255,"status":100,"phases":4208,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":297,"conditions":4209,"interventions":4210},[83],[18],[107,252,253,846,108,238],{"nctId":98,"briefTitle":99,"status":100,"phases":4212,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":4213,"interventions":4214},[83],[24],[107,49,108],{"trials":4216,"activeCount":94},[],{"trials":4218,"activeCount":94},[],{"trials":4220,"activeCount":94},[],{"trials":4222,"activeCount":94},[],{"intervention":2932,"totalTrials":170,"cells":4224},{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4241,"PHASE3":4243,"PHASE4":4245,"NA":4247},{"trials":4226,"activeCount":94},[],{"trials":4228,"activeCount":94},[4229,4233],{"nctId":2925,"briefTitle":2926,"status":131,"phases":4230,"primaryCompletion":2928,"completion":2929,"start":2810,"enrollment":145,"conditions":4231,"interventions":4232},[83],[32],[2932,496,2854],{"nctId":4234,"briefTitle":4235,"status":100,"phases":4236,"primaryCompletion":2374,"completion":4237,"start":2255,"enrollment":4238,"conditions":4239,"interventions":4240},"NCT00633529","Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC",[83],"2011-03",36,[572],[2932],{"trials":4242,"activeCount":94},[],{"trials":4244,"activeCount":94},[],{"trials":4246,"activeCount":94},[],{"trials":4248,"activeCount":94},[],{"intervention":4250,"totalTrials":170,"cells":4251},"AS703569",{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4273,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4253,"activeCount":94},[],{"trials":4255,"activeCount":94},[4256,4265],{"nctId":4257,"briefTitle":4258,"status":100,"phases":4259,"primaryCompletion":4260,"completion":4260,"start":4261,"enrollment":4262,"conditions":4263,"interventions":4264},"NCT00391521","AS703569 Phase I in Patients With Solid Tumours",[83],"2010-06","2006-08",104,[21],[4250,4250,4250],{"nctId":4266,"briefTitle":4267,"status":131,"phases":4268,"primaryCompletion":2851,"completion":2929,"start":1465,"enrollment":4269,"conditions":4270,"interventions":4272},"NCT01080664","A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies",[83],124,[4271],"Haematological Malignancies",[4250,4250],{"trials":4274,"activeCount":94},[],{"trials":4276,"activeCount":94},[],{"trials":4278,"activeCount":94},[],{"trials":4280,"activeCount":94},[],{"intervention":161,"totalTrials":170,"cells":4282},{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4295,"PHASE3":4297,"PHASE4":4299,"NA":4301},{"trials":4284,"activeCount":94},[],{"trials":4286,"activeCount":94},[4287,4291],{"nctId":1290,"briefTitle":1291,"status":131,"phases":4288,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":170,"conditions":4289,"interventions":4290},[83],[1296],[161,253,846],{"nctId":151,"briefTitle":152,"status":100,"phases":4292,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":4293,"interventions":4294},[83],[159,21],[161,161,49],{"trials":4296,"activeCount":94},[],{"trials":4298,"activeCount":94},[],{"trials":4300,"activeCount":94},[],{"trials":4302,"activeCount":94},[],{"intervention":4304,"totalTrials":205,"cells":4305},"M1231",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4319,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4307,"activeCount":94},[],{"trials":4309,"activeCount":94},[4310],{"nctId":4311,"briefTitle":4312,"status":100,"phases":4313,"primaryCompletion":644,"completion":644,"start":4314,"enrollment":4315,"conditions":4316,"interventions":4318},"NCT04695847","M1231 in Participants With Solid Tumors",[83],"2021-01-13",23,[648,4317,572],"Esophageal Cancer",[4304,4304],{"trials":4320,"activeCount":94},[],{"trials":4322,"activeCount":94},[],{"trials":4324,"activeCount":94},[],{"trials":4326,"activeCount":94},[],{"intervention":1270,"totalTrials":205,"cells":4328},{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4337,"PHASE3":4339,"PHASE4":4341,"NA":4343},{"trials":4330,"activeCount":94},[],{"trials":4332,"activeCount":94},[4333],{"nctId":1262,"briefTitle":1263,"status":100,"phases":4334,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":4335,"interventions":4336},[83],[27],[1270,1271,1272,1273,1274,253],{"trials":4338,"activeCount":94},[],{"trials":4340,"activeCount":94},[],{"trials":4342,"activeCount":94},[],{"trials":4344,"activeCount":94},[],{"intervention":1271,"totalTrials":205,"cells":4346},{"EARLY_PHASE1":4347,"PHASE1":4349,"PHASE2":4355,"PHASE3":4357,"PHASE4":4359,"NA":4361},{"trials":4348,"activeCount":94},[],{"trials":4350,"activeCount":94},[4351],{"nctId":1262,"briefTitle":1263,"status":100,"phases":4352,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":4353,"interventions":4354},[83],[27],[1270,1271,1272,1273,1274,253],{"trials":4356,"activeCount":94},[],{"trials":4358,"activeCount":94},[],{"trials":4360,"activeCount":94},[],{"trials":4362,"activeCount":94},[],{"intervention":1272,"totalTrials":205,"cells":4364},{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4373,"PHASE3":4375,"PHASE4":4377,"NA":4379},{"trials":4366,"activeCount":94},[],{"trials":4368,"activeCount":94},[4369],{"nctId":1262,"briefTitle":1263,"status":100,"phases":4370,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":4371,"interventions":4372},[83],[27],[1270,1271,1272,1273,1274,253],{"trials":4374,"activeCount":94},[],{"trials":4376,"activeCount":94},[],{"trials":4378,"activeCount":94},[],{"trials":4380,"activeCount":94},[],{"intervention":1273,"totalTrials":205,"cells":4382},{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4397},{"trials":4384,"activeCount":94},[],{"trials":4386,"activeCount":94},[4387],{"nctId":1262,"briefTitle":1263,"status":100,"phases":4388,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":4389,"interventions":4390},[83],[27],[1270,1271,1272,1273,1274,253],{"trials":4392,"activeCount":94},[],{"trials":4394,"activeCount":94},[],{"trials":4396,"activeCount":94},[],{"trials":4398,"activeCount":94},[],{"intervention":1274,"totalTrials":205,"cells":4400},{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4409,"PHASE3":4411,"PHASE4":4413,"NA":4415},{"trials":4402,"activeCount":94},[],{"trials":4404,"activeCount":94},[4405],{"nctId":1262,"briefTitle":1263,"status":100,"phases":4406,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":135,"conditions":4407,"interventions":4408},[83],[27],[1270,1271,1272,1273,1274,253],{"trials":4410,"activeCount":94},[],{"trials":4412,"activeCount":94},[],{"trials":4414,"activeCount":94},[],{"trials":4416,"activeCount":94},[],{"intervention":4418,"totalTrials":205,"cells":4419},"Test: Follitropin alfa",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4435,"PHASE3":4437,"PHASE4":4439,"NA":4441},{"trials":4421,"activeCount":94},[],{"trials":4423,"activeCount":94},[4424],{"nctId":4425,"briefTitle":4426,"status":100,"phases":4427,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":2349,"conditions":4430,"interventions":4432},"NCT07097259","A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants",[83],"2025-12-23","2025-07-21",[4431],"Hypogonadism",[4418,4433,4434],"Reference: Follitropin alfa","Zoladex",{"trials":4436,"activeCount":94},[],{"trials":4438,"activeCount":94},[],{"trials":4440,"activeCount":94},[],{"trials":4442,"activeCount":94},[],{"intervention":4433,"totalTrials":205,"cells":4444},{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4453,"PHASE3":4455,"PHASE4":4457,"NA":4459},{"trials":4446,"activeCount":94},[],{"trials":4448,"activeCount":94},[4449],{"nctId":4425,"briefTitle":4426,"status":100,"phases":4450,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":2349,"conditions":4451,"interventions":4452},[83],[4431],[4418,4433,4434],{"trials":4454,"activeCount":94},[],{"trials":4456,"activeCount":94},[],{"trials":4458,"activeCount":94},[],{"trials":4460,"activeCount":94},[],{"intervention":4434,"totalTrials":205,"cells":4462},{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4471,"PHASE3":4473,"PHASE4":4475,"NA":4477},{"trials":4464,"activeCount":94},[],{"trials":4466,"activeCount":94},[4467],{"nctId":4425,"briefTitle":4426,"status":100,"phases":4468,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":2349,"conditions":4469,"interventions":4470},[83],[4431],[4418,4433,4434],{"trials":4472,"activeCount":94},[],{"trials":4474,"activeCount":94},[],{"trials":4476,"activeCount":94},[],{"trials":4478,"activeCount":94},[],{"intervention":4480,"totalTrials":205,"cells":4481},"Part 1: M8891",{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4483,"activeCount":94},[],{"trials":4485,"activeCount":94},[4486],{"nctId":4487,"briefTitle":4488,"status":131,"phases":4489,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":4492,"conditions":4493,"interventions":4495},"NCT03138538","M8891 First in Human in Solid Tumors",[83],"2020-09-16","2017-08-08",27,[27,4494],"Metastatic Renal Cell Carcinoma",[4480],{"trials":4497,"activeCount":94},[],{"trials":4499,"activeCount":94},[],{"trials":4501,"activeCount":94},[],{"trials":4503,"activeCount":94},[],{"intervention":2834,"totalTrials":205,"cells":4505},{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4514,"PHASE3":4516,"PHASE4":4518,"NA":4520},{"trials":4507,"activeCount":94},[],{"trials":4509,"activeCount":94},[4510],{"nctId":2826,"briefTitle":2827,"status":131,"phases":4511,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":4512,"interventions":4513},[83],[18],[1576,1576,2834,2834],{"trials":4515,"activeCount":94},[],{"trials":4517,"activeCount":94},[],{"trials":4519,"activeCount":94},[],{"trials":4521,"activeCount":94},[],{"intervention":4523,"totalTrials":205,"cells":4524},"MSC2015103B",{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4537,"PHASE3":4539,"PHASE4":4541,"NA":4543},{"trials":4526,"activeCount":94},[],{"trials":4528,"activeCount":94},[4529],{"nctId":4530,"briefTitle":4531,"status":131,"phases":4532,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":1896,"conditions":4535,"interventions":4536},"NCT01453387","MSC2015103B in Solid Tumors",[83],"2013-07","2011-09",[18],[4523,4523],{"trials":4538,"activeCount":94},[],{"trials":4540,"activeCount":94},[],{"trials":4542,"activeCount":94},[],{"trials":4544,"activeCount":94},[],{"intervention":1374,"totalTrials":205,"cells":4546},{"EARLY_PHASE1":4547,"PHASE1":4549,"PHASE2":4555,"PHASE3":4557,"PHASE4":4559,"NA":4561},{"trials":4548,"activeCount":94},[],{"trials":4550,"activeCount":94},[4551],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4552,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4553,"interventions":4554},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4556,"activeCount":94},[],{"trials":4558,"activeCount":94},[],{"trials":4560,"activeCount":94},[],{"trials":4562,"activeCount":94},[],{"intervention":1375,"totalTrials":205,"cells":4564},{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4566,"activeCount":94},[],{"trials":4568,"activeCount":94},[4569],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4570,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4571,"interventions":4572},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4574,"activeCount":94},[],{"trials":4576,"activeCount":94},[],{"trials":4578,"activeCount":94},[],{"trials":4580,"activeCount":94},[],{"intervention":1376,"totalTrials":205,"cells":4582},{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4584,"activeCount":94},[],{"trials":4586,"activeCount":94},[4587],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4588,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4589,"interventions":4590},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4592,"activeCount":94},[],{"trials":4594,"activeCount":94},[],{"trials":4596,"activeCount":94},[],{"trials":4598,"activeCount":94},[],{"intervention":1377,"totalTrials":205,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4609,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4602,"activeCount":94},[],{"trials":4604,"activeCount":94},[4605],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4606,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4607,"interventions":4608},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4610,"activeCount":94},[],{"trials":4612,"activeCount":94},[],{"trials":4614,"activeCount":94},[],{"trials":4616,"activeCount":94},[],{"intervention":1378,"totalTrials":205,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4620,"activeCount":94},[],{"trials":4622,"activeCount":94},[4623],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4624,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4625,"interventions":4626},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4628,"activeCount":94},[],{"trials":4630,"activeCount":94},[],{"trials":4632,"activeCount":94},[],{"trials":4634,"activeCount":94},[],{"intervention":1379,"totalTrials":205,"cells":4636},{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4645,"PHASE3":4647,"PHASE4":4649,"NA":4651},{"trials":4638,"activeCount":94},[],{"trials":4640,"activeCount":94},[4641],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4642,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4643,"interventions":4644},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4646,"activeCount":94},[],{"trials":4648,"activeCount":94},[],{"trials":4650,"activeCount":94},[],{"trials":4652,"activeCount":94},[],{"intervention":1380,"totalTrials":205,"cells":4654},{"EARLY_PHASE1":4655,"PHASE1":4657,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4656,"activeCount":94},[],{"trials":4658,"activeCount":94},[4659],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4660,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4661,"interventions":4662},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4664,"activeCount":94},[],{"trials":4666,"activeCount":94},[],{"trials":4668,"activeCount":94},[],{"trials":4670,"activeCount":94},[],{"intervention":1381,"totalTrials":205,"cells":4672},{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4681,"PHASE3":4683,"PHASE4":4685,"NA":4687},{"trials":4674,"activeCount":94},[],{"trials":4676,"activeCount":94},[4677],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4678,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4679,"interventions":4680},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4682,"activeCount":94},[],{"trials":4684,"activeCount":94},[],{"trials":4686,"activeCount":94},[],{"trials":4688,"activeCount":94},[],{"intervention":1382,"totalTrials":205,"cells":4690},{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4699,"PHASE3":4701,"PHASE4":4703,"NA":4705},{"trials":4692,"activeCount":94},[],{"trials":4694,"activeCount":94},[4695],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4696,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4697,"interventions":4698},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4700,"activeCount":94},[],{"trials":4702,"activeCount":94},[],{"trials":4704,"activeCount":94},[],{"trials":4706,"activeCount":94},[],{"intervention":1383,"totalTrials":205,"cells":4708},{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4717,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4710,"activeCount":94},[],{"trials":4712,"activeCount":94},[4713],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4714,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4715,"interventions":4716},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4718,"activeCount":94},[],{"trials":4720,"activeCount":94},[],{"trials":4722,"activeCount":94},[],{"trials":4724,"activeCount":94},[],{"intervention":1384,"totalTrials":205,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4735,"PHASE3":4737,"PHASE4":4739,"NA":4741},{"trials":4728,"activeCount":94},[],{"trials":4730,"activeCount":94},[4731],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4732,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4733,"interventions":4734},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4736,"activeCount":94},[],{"trials":4738,"activeCount":94},[],{"trials":4740,"activeCount":94},[],{"trials":4742,"activeCount":94},[],{"intervention":1385,"totalTrials":205,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4753,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4746,"activeCount":94},[],{"trials":4748,"activeCount":94},[4749],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4750,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4751,"interventions":4752},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4754,"activeCount":94},[],{"trials":4756,"activeCount":94},[],{"trials":4758,"activeCount":94},[],{"trials":4760,"activeCount":94},[],{"intervention":1386,"totalTrials":205,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4764,"activeCount":94},[],{"trials":4766,"activeCount":94},[4767],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4768,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4769,"interventions":4770},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4772,"activeCount":94},[],{"trials":4774,"activeCount":94},[],{"trials":4776,"activeCount":94},[],{"trials":4778,"activeCount":94},[],{"intervention":1387,"totalTrials":205,"cells":4780},{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4795},{"trials":4782,"activeCount":94},[],{"trials":4784,"activeCount":94},[4785],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4786,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4787,"interventions":4788},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4790,"activeCount":94},[],{"trials":4792,"activeCount":94},[],{"trials":4794,"activeCount":94},[],{"trials":4796,"activeCount":94},[],{"intervention":1388,"totalTrials":205,"cells":4798},{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4813},{"trials":4800,"activeCount":94},[],{"trials":4802,"activeCount":94},[4803],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4804,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4805,"interventions":4806},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4808,"activeCount":94},[],{"trials":4810,"activeCount":94},[],{"trials":4812,"activeCount":94},[],{"trials":4814,"activeCount":94},[],{"intervention":1389,"totalTrials":205,"cells":4816},{"EARLY_PHASE1":4817,"PHASE1":4819,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4818,"activeCount":94},[],{"trials":4820,"activeCount":94},[4821],{"nctId":1364,"briefTitle":1365,"status":100,"phases":4822,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":1370,"conditions":4823,"interventions":4824},[83],[1372,18],[1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,108],{"trials":4826,"activeCount":94},[],{"trials":4828,"activeCount":94},[],{"trials":4830,"activeCount":94},[],{"trials":4832,"activeCount":94},[],{"intervention":847,"totalTrials":205,"cells":4834},{"EARLY_PHASE1":4835,"PHASE1":4837,"PHASE2":4843,"PHASE3":4845,"PHASE4":4847,"NA":4849},{"trials":4836,"activeCount":94},[],{"trials":4838,"activeCount":94},[4839],{"nctId":840,"briefTitle":841,"status":176,"phases":4840,"primaryCompletion":843,"completion":843,"start":843,"enrollment":94,"conditions":4841,"interventions":4842},[83],[27],[310,108,846,847,848,848,108],{"trials":4844,"activeCount":94},[],{"trials":4846,"activeCount":94},[],{"trials":4848,"activeCount":94},[],{"trials":4850,"activeCount":94},[],{"intervention":848,"totalTrials":205,"cells":4852},{"EARLY_PHASE1":4853,"PHASE1":4855,"PHASE2":4861,"PHASE3":4863,"PHASE4":4865,"NA":4867},{"trials":4854,"activeCount":94},[],{"trials":4856,"activeCount":94},[4857],{"nctId":840,"briefTitle":841,"status":176,"phases":4858,"primaryCompletion":843,"completion":843,"start":843,"enrollment":94,"conditions":4859,"interventions":4860},[83],[27],[310,108,846,847,848,848,108],{"trials":4862,"activeCount":94},[],{"trials":4864,"activeCount":94},[],{"trials":4866,"activeCount":94},[],{"trials":4868,"activeCount":94},[],{"intervention":4870,"totalTrials":205,"cells":4871},"MSC2363318A",{"EARLY_PHASE1":4872,"PHASE1":4874,"PHASE2":4887,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4873,"activeCount":94},[],{"trials":4875,"activeCount":94},[4876],{"nctId":4877,"briefTitle":4878,"status":100,"phases":4879,"primaryCompletion":4880,"completion":4880,"start":4881,"enrollment":4882,"conditions":4883,"interventions":4884},"NCT01971515","First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies",[83],"2018-08-09","2013-12-13",101,[1372],[4870,4885,4886],"MSC2363318A plus Trastuzumab","MSC2363318A plus Tamoxifen",{"trials":4888,"activeCount":94},[],{"trials":4890,"activeCount":94},[],{"trials":4892,"activeCount":94},[],{"trials":4894,"activeCount":94},[],{"intervention":4885,"totalTrials":205,"cells":4896},{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4905,"PHASE3":4907,"PHASE4":4909,"NA":4911},{"trials":4898,"activeCount":94},[],{"trials":4900,"activeCount":94},[4901],{"nctId":4877,"briefTitle":4878,"status":100,"phases":4902,"primaryCompletion":4880,"completion":4880,"start":4881,"enrollment":4882,"conditions":4903,"interventions":4904},[83],[1372],[4870,4885,4886],{"trials":4906,"activeCount":94},[],{"trials":4908,"activeCount":94},[],{"trials":4910,"activeCount":94},[],{"trials":4912,"activeCount":94},[],{"intervention":4886,"totalTrials":205,"cells":4914},{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4923,"PHASE3":4925,"PHASE4":4927,"NA":4929},{"trials":4916,"activeCount":94},[],{"trials":4918,"activeCount":94},[4919],{"nctId":4877,"briefTitle":4878,"status":100,"phases":4920,"primaryCompletion":4880,"completion":4880,"start":4881,"enrollment":4882,"conditions":4921,"interventions":4922},[83],[1372],[4870,4885,4886],{"trials":4924,"activeCount":94},[],{"trials":4926,"activeCount":94},[],{"trials":4928,"activeCount":94},[],{"trials":4930,"activeCount":94},[],{"intervention":4932,"totalTrials":205,"cells":4933},"EMD 1204831",{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4946,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4935,"activeCount":94},[],{"trials":4937,"activeCount":94},[4938],{"nctId":4939,"briefTitle":4940,"status":131,"phases":4941,"primaryCompletion":4942,"start":4943,"enrollment":1041,"conditions":4944,"interventions":4945},"NCT01110083","First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors",[83],"2012-03","2010-04",[21],[4932],{"trials":4947,"activeCount":94},[],{"trials":4949,"activeCount":94},[],{"trials":4951,"activeCount":94},[],{"trials":4953,"activeCount":94},[],{"intervention":4955,"totalTrials":205,"cells":4956},"EMD 273066",{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4969,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4958,"activeCount":94},[],{"trials":4960,"activeCount":94},[4961],{"nctId":4962,"briefTitle":4963,"status":100,"phases":4964,"primaryCompletion":1473,"completion":1495,"start":4965,"enrollment":10,"conditions":4966,"interventions":4968},"NCT00132522","EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide",[83],"2005-05",[24,32,4967,1898],"Carcinoma, Non-small-cell Lung",[4955],{"trials":4970,"activeCount":94},[],{"trials":4972,"activeCount":94},[],{"trials":4974,"activeCount":94},[],{"trials":4976,"activeCount":94},[],{"intervention":4978,"totalTrials":205,"cells":4979},"M4112",{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4992,"PHASE3":4994,"PHASE4":4996,"NA":4998},{"trials":4981,"activeCount":94},[],{"trials":4983,"activeCount":94},[4984],{"nctId":4985,"briefTitle":4986,"status":131,"phases":4987,"primaryCompletion":4988,"completion":4988,"start":4989,"enrollment":90,"conditions":4990,"interventions":4991},"NCT03306420","First-in-Human Study of MS201408-0005A as Single Agent and in Combinations",[83],"2019-01-14","2017-10-03",[167],[4978],{"trials":4993,"activeCount":94},[],{"trials":4995,"activeCount":94},[],{"trials":4997,"activeCount":94},[],{"trials":4999,"activeCount":94},[],{"intervention":5001,"totalTrials":205,"cells":5002},"MSC2156119J",{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5015,"PHASE3":5017,"PHASE4":5019,"NA":5021},{"trials":5004,"activeCount":94},[],{"trials":5006,"activeCount":94},[5007],{"nctId":5008,"briefTitle":5009,"status":100,"phases":5010,"primaryCompletion":5011,"completion":5011,"start":1572,"enrollment":3498,"conditions":5012,"interventions":5014},"NCT01014936","First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",[83],"2015-10-31",[5013],"Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available",[5001],{"trials":5016,"activeCount":94},[],{"trials":5018,"activeCount":94},[],{"trials":5020,"activeCount":94},[],{"trials":5022,"activeCount":94},[],{"intervention":5024,"totalTrials":205,"cells":5025},"M4076",{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5038,"PHASE3":5040,"PHASE4":5042,"NA":5044},{"trials":5027,"activeCount":94},[],{"trials":5029,"activeCount":94},[5030],{"nctId":5031,"briefTitle":5032,"status":100,"phases":5033,"primaryCompletion":5034,"completion":5034,"start":5035,"enrollment":1636,"conditions":5036,"interventions":5037},"NCT04882917","First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)",[83],"2023-03-31","2021-05-24",[27],[5024],{"trials":5039,"activeCount":94},[],{"trials":5041,"activeCount":94},[],{"trials":5043,"activeCount":94},[],{"trials":5045,"activeCount":94},[],{"intervention":138,"totalTrials":205,"cells":5047},{"EARLY_PHASE1":5048,"PHASE1":5050,"PHASE2":5056,"PHASE3":5058,"PHASE4":5060,"NA":5062},{"trials":5049,"activeCount":94},[],{"trials":5051,"activeCount":94},[5052],{"nctId":129,"briefTitle":130,"status":131,"phases":5053,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":5054,"interventions":5055},[83],[27],[49,138,49,138,49],{"trials":5057,"activeCount":94},[],{"trials":5059,"activeCount":94},[],{"trials":5061,"activeCount":94},[],{"trials":5063,"activeCount":94},[],{"intervention":5065,"totalTrials":205,"cells":5066},"M3258",{"EARLY_PHASE1":5067,"PHASE1":5069,"PHASE2":5081,"PHASE3":5083,"PHASE4":5085,"NA":5087},{"trials":5068,"activeCount":94},[],{"trials":5070,"activeCount":94},[5071],{"nctId":5072,"briefTitle":5073,"status":131,"phases":5074,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":19,"conditions":5077,"interventions":5079},"NCT04075721","First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone",[83],"2021-04-01","2019-09-26",[5078],"Multiple Myeloma",[5065,5080],"M3258 20 mg",{"trials":5082,"activeCount":94},[],{"trials":5084,"activeCount":94},[],{"trials":5086,"activeCount":94},[],{"trials":5088,"activeCount":94},[],{"intervention":5080,"totalTrials":205,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":94},[],{"trials":5094,"activeCount":94},[5095],{"nctId":5072,"briefTitle":5073,"status":131,"phases":5096,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":19,"conditions":5097,"interventions":5098},[83],[5078],[5065,5080],{"trials":5100,"activeCount":94},[],{"trials":5102,"activeCount":94},[],{"trials":5104,"activeCount":94},[],{"trials":5106,"activeCount":94},[],{"intervention":5108,"totalTrials":205,"cells":5109},"r-hGH liquid",{"EARLY_PHASE1":5110,"PHASE1":5112,"PHASE2":5125,"PHASE3":5127,"PHASE4":5129,"NA":5131},{"trials":5111,"activeCount":94},[],{"trials":5113,"activeCount":94},[5114],{"nctId":5115,"briefTitle":5116,"status":100,"phases":5117,"primaryCompletion":5118,"start":2811,"enrollment":5119,"conditions":5120,"interventions":5123},"NCT01034735","r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial",[83],"2008-08",30,[5121,5122],"Growth Failure","Growth Hormone Deficiency",[5108,5108,5124],"r-hGH freeze-dried",{"trials":5126,"activeCount":94},[],{"trials":5128,"activeCount":94},[],{"trials":5130,"activeCount":94},[],{"trials":5132,"activeCount":94},[],{"intervention":5124,"totalTrials":205,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5143,"PHASE3":5145,"PHASE4":5147,"NA":5149},{"trials":5136,"activeCount":94},[],{"trials":5138,"activeCount":94},[5139],{"nctId":5115,"briefTitle":5116,"status":100,"phases":5140,"primaryCompletion":5118,"start":2811,"enrollment":5119,"conditions":5141,"interventions":5142},[83],[5121,5122],[5108,5108,5124],{"trials":5144,"activeCount":94},[],{"trials":5146,"activeCount":94},[],{"trials":5148,"activeCount":94},[],{"trials":5150,"activeCount":94},[],{"intervention":3042,"totalTrials":205,"cells":5152},{"EARLY_PHASE1":5153,"PHASE1":5155,"PHASE2":5161,"PHASE3":5163,"PHASE4":5165,"NA":5167},{"trials":5154,"activeCount":94},[],{"trials":5156,"activeCount":94},[5157],{"nctId":3032,"briefTitle":3033,"status":100,"phases":5158,"primaryCompletion":1918,"completion":1918,"start":3035,"enrollment":1614,"conditions":5159,"interventions":5160},[83],[3037,3038,546,3039,3040,32],[3042,3025,3042,3025],{"trials":5162,"activeCount":94},[],{"trials":5164,"activeCount":94},[],{"trials":5166,"activeCount":94},[],{"trials":5168,"activeCount":94},[],{"intervention":5170,"totalTrials":205,"cells":5171},"VX-984 120 mg + PLD 40 mg\u002Fm^2",{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5187,"PHASE3":5189,"PHASE4":5191,"NA":5193},{"trials":5173,"activeCount":94},[],{"trials":5175,"activeCount":94},[5176],{"nctId":5177,"briefTitle":5178,"status":100,"phases":5179,"primaryCompletion":5180,"completion":5180,"start":5181,"enrollment":90,"conditions":5182,"interventions":5183},"NCT02644278","First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic\u002FPharmacodynamic Profile of VX-984 in Combination With Chemotherapy",[83],"2017-10-19","2016-02-29",[18],[5170,5184,5185,5186],"VX-984 240 mg + PLD 40 mg\u002Fm^2","VX-984 480 mg + PLD 40 mg\u002Fm^2","VX-984 720 mg + PLD 40 mg\u002Fm^2",{"trials":5188,"activeCount":94},[],{"trials":5190,"activeCount":94},[],{"trials":5192,"activeCount":94},[],{"trials":5194,"activeCount":94},[],{"intervention":5184,"totalTrials":205,"cells":5196},{"EARLY_PHASE1":5197,"PHASE1":5199,"PHASE2":5205,"PHASE3":5207,"PHASE4":5209,"NA":5211},{"trials":5198,"activeCount":94},[],{"trials":5200,"activeCount":94},[5201],{"nctId":5177,"briefTitle":5178,"status":100,"phases":5202,"primaryCompletion":5180,"completion":5180,"start":5181,"enrollment":90,"conditions":5203,"interventions":5204},[83],[18],[5170,5184,5185,5186],{"trials":5206,"activeCount":94},[],{"trials":5208,"activeCount":94},[],{"trials":5210,"activeCount":94},[],{"trials":5212,"activeCount":94},[],{"intervention":5185,"totalTrials":205,"cells":5214},{"EARLY_PHASE1":5215,"PHASE1":5217,"PHASE2":5223,"PHASE3":5225,"PHASE4":5227,"NA":5229},{"trials":5216,"activeCount":94},[],{"trials":5218,"activeCount":94},[5219],{"nctId":5177,"briefTitle":5178,"status":100,"phases":5220,"primaryCompletion":5180,"completion":5180,"start":5181,"enrollment":90,"conditions":5221,"interventions":5222},[83],[18],[5170,5184,5185,5186],{"trials":5224,"activeCount":94},[],{"trials":5226,"activeCount":94},[],{"trials":5228,"activeCount":94},[],{"trials":5230,"activeCount":94},[],{"intervention":5186,"totalTrials":205,"cells":5232},{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5241,"PHASE3":5243,"PHASE4":5245,"NA":5247},{"trials":5234,"activeCount":94},[],{"trials":5236,"activeCount":94},[5237],{"nctId":5177,"briefTitle":5178,"status":100,"phases":5238,"primaryCompletion":5180,"completion":5180,"start":5181,"enrollment":90,"conditions":5239,"interventions":5240},[83],[18],[5170,5184,5185,5186],{"trials":5242,"activeCount":94},[],{"trials":5244,"activeCount":94},[],{"trials":5246,"activeCount":94},[],{"trials":5248,"activeCount":94},[],{"intervention":311,"totalTrials":205,"cells":5250},{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5259,"PHASE3":5261,"PHASE4":5263,"NA":5265},{"trials":5252,"activeCount":94},[],{"trials":5254,"activeCount":94},[5255],{"nctId":303,"briefTitle":304,"status":131,"phases":5256,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":5257,"interventions":5258},[83],[18],[310,238,301,311,275,312],{"trials":5260,"activeCount":94},[],{"trials":5262,"activeCount":94},[],{"trials":5264,"activeCount":94},[],{"trials":5266,"activeCount":94},[],{"intervention":312,"totalTrials":205,"cells":5268},{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5277,"PHASE3":5279,"PHASE4":5281,"NA":5283},{"trials":5270,"activeCount":94},[],{"trials":5272,"activeCount":94},[5273],{"nctId":303,"briefTitle":304,"status":131,"phases":5274,"primaryCompletion":306,"completion":306,"start":307,"enrollment":104,"conditions":5275,"interventions":5276},[83],[18],[310,238,301,311,275,312],{"trials":5278,"activeCount":94},[],{"trials":5280,"activeCount":94},[],{"trials":5282,"activeCount":94},[],{"trials":5284,"activeCount":94},[],{"intervention":5286,"totalTrials":205,"cells":5287},"MSC2364447C",{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5300,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5289,"activeCount":94},[],{"trials":5291,"activeCount":94},[5292],{"nctId":5293,"briefTitle":5294,"status":100,"phases":5295,"primaryCompletion":5296,"completion":5296,"start":5297,"enrollment":3864,"conditions":5298,"interventions":5299},"NCT02537028","MSC2364447C Phase 1b in Systemic Lupus Erythematosus",[83],"2016-10-04","2015-11-30",[1735],[5286,5286],{"trials":5301,"activeCount":94},[],{"trials":5303,"activeCount":94},[],{"trials":5305,"activeCount":94},[],{"trials":5307,"activeCount":94},[],{"intervention":5309,"totalTrials":205,"cells":5310},"Part 1: Sym004 6 mg\u002Fkg + Cisplatin\u002FGemcitabine",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5325,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5312,"activeCount":94},[],{"trials":5314,"activeCount":94},[5315],{"nctId":5316,"briefTitle":5317,"status":131,"phases":5318,"primaryCompletion":5319,"completion":5319,"start":3950,"enrollment":90,"conditions":5320,"interventions":5321},"NCT02083679","Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer",[83],"2015-08",[217],[5309,5322,5323,5324],"Part 1: Sym004 6 mg\u002Fkg + Cisplatin\u002FPemetrexed","Part 1: Sym004 6 mg\u002Fkg + Carboplatin\u002FPaclitaxel","Part 1: Sym004 6\u002F12 mg\u002Fkg + Carboplatin\u002FPaclitaxel",{"trials":5326,"activeCount":94},[],{"trials":5328,"activeCount":94},[],{"trials":5330,"activeCount":94},[],{"trials":5332,"activeCount":94},[],{"intervention":5322,"totalTrials":205,"cells":5334},{"EARLY_PHASE1":5335,"PHASE1":5337,"PHASE2":5343,"PHASE3":5345,"PHASE4":5347,"NA":5349},{"trials":5336,"activeCount":94},[],{"trials":5338,"activeCount":94},[5339],{"nctId":5316,"briefTitle":5317,"status":131,"phases":5340,"primaryCompletion":5319,"completion":5319,"start":3950,"enrollment":90,"conditions":5341,"interventions":5342},[83],[217],[5309,5322,5323,5324],{"trials":5344,"activeCount":94},[],{"trials":5346,"activeCount":94},[],{"trials":5348,"activeCount":94},[],{"trials":5350,"activeCount":94},[],{"intervention":5323,"totalTrials":205,"cells":5352},{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5361,"PHASE3":5363,"PHASE4":5365,"NA":5367},{"trials":5354,"activeCount":94},[],{"trials":5356,"activeCount":94},[5357],{"nctId":5316,"briefTitle":5317,"status":131,"phases":5358,"primaryCompletion":5319,"completion":5319,"start":3950,"enrollment":90,"conditions":5359,"interventions":5360},[83],[217],[5309,5322,5323,5324],{"trials":5362,"activeCount":94},[],{"trials":5364,"activeCount":94},[],{"trials":5366,"activeCount":94},[],{"trials":5368,"activeCount":94},[],{"intervention":5324,"totalTrials":205,"cells":5370},{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5379,"PHASE3":5381,"PHASE4":5383,"NA":5385},{"trials":5372,"activeCount":94},[],{"trials":5374,"activeCount":94},[5375],{"nctId":5316,"briefTitle":5317,"status":131,"phases":5376,"primaryCompletion":5319,"completion":5319,"start":3950,"enrollment":90,"conditions":5377,"interventions":5378},[83],[217],[5309,5322,5323,5324],{"trials":5380,"activeCount":94},[],{"trials":5382,"activeCount":94},[],{"trials":5384,"activeCount":94},[],{"trials":5386,"activeCount":94},[],{"intervention":5388,"totalTrials":205,"cells":5389},"M1069",{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5403,"PHASE3":5405,"PHASE4":5407,"NA":5409},{"trials":5391,"activeCount":94},[],{"trials":5393,"activeCount":94},[5394],{"nctId":5395,"briefTitle":5396,"status":131,"phases":5397,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":90,"conditions":5401,"interventions":5402},"NCT05198349","First in Human Study of M1069 in Advanced Solid Tumors",[83],"2023-05-09","2023-08-10","2022-03-02",[167],[5388],{"trials":5404,"activeCount":94},[],{"trials":5406,"activeCount":94},[],{"trials":5408,"activeCount":94},[],{"trials":5410,"activeCount":94},[],{"intervention":5412,"totalTrials":205,"cells":5413},"M3541",{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5427,"PHASE3":5429,"PHASE4":5431,"NA":5433},{"trials":5415,"activeCount":94},[],{"trials":5417,"activeCount":94},[5418],{"nctId":5419,"briefTitle":5420,"status":131,"phases":5421,"primaryCompletion":5422,"completion":5423,"start":5424,"enrollment":90,"conditions":5425,"interventions":5426},"NCT03225105","M3541 in Combination With Radiotherapy in Solid Tumors",[83],"2019-09-02","2020-04-27","2017-09-06",[21],[5412],{"trials":5428,"activeCount":94},[],{"trials":5430,"activeCount":94},[],{"trials":5432,"activeCount":94},[],{"trials":5434,"activeCount":94},[],{"intervention":5436,"totalTrials":205,"cells":5437},"MSB0011359C",{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5451,"PHASE3":5453,"PHASE4":5455,"NA":5457},{"trials":5439,"activeCount":94},[],{"trials":5441,"activeCount":94},[5442],{"nctId":5443,"briefTitle":5444,"status":100,"phases":5445,"primaryCompletion":5446,"completion":5446,"start":5447,"enrollment":5448,"conditions":5449,"interventions":5450},"NCT02517398","MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors",[83],"2022-05-23","2015-08-31",600,[21],[5436],{"trials":5452,"activeCount":94},[],{"trials":5454,"activeCount":94},[],{"trials":5456,"activeCount":94},[],{"trials":5458,"activeCount":94},[],{"intervention":2328,"totalTrials":1550,"cells":5460},{"EARLY_PHASE1":5461,"PHASE1":5463,"PHASE2":5465,"PHASE3":5471,"PHASE4":5486,"NA":5488},{"trials":5462,"activeCount":94},[],{"trials":5464,"activeCount":94},[],{"trials":5466,"activeCount":94},[5467],{"nctId":3614,"briefTitle":3615,"status":100,"phases":5468,"primaryCompletion":3617,"completion":1039,"start":3618,"enrollment":3619,"conditions":5469,"interventions":5470},[84],[15],[2328,3605],{"trials":5472,"activeCount":94},[5473,5477],{"nctId":2319,"briefTitle":2320,"status":100,"phases":5474,"primaryCompletion":2322,"completion":2323,"start":2324,"enrollment":2325,"conditions":5475,"interventions":5476},[85],[15],[2328,2308],{"nctId":5478,"briefTitle":5479,"status":100,"phases":5480,"primaryCompletion":5481,"completion":5481,"start":5482,"enrollment":5483,"conditions":5484,"interventions":5485},"NCT00641537","CLARITY Extension Study",[85],"2011-12-31","2008-02-29",867,[1050],[2328,2328,2328],{"trials":5487,"activeCount":94},[],{"trials":5489,"activeCount":94},[5490,5499],{"nctId":5491,"briefTitle":5492,"status":100,"phases":5493,"primaryCompletion":5494,"completion":5494,"start":5495,"enrollment":5496,"conditions":5497,"interventions":5498},"NCT03933202","A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)",[],"2024-11-11","2019-07-22",291,[15],[2328],{"nctId":5500,"briefTitle":5501,"status":100,"phases":5502,"primaryCompletion":5503,"completion":5503,"start":5504,"enrollment":5505,"conditions":5506,"interventions":5507},"NCT03933215","A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)",[],"2024-03-30","2019-05-21",100,[15],[2328],{"intervention":1118,"totalTrials":30,"cells":5509},{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5514,"PHASE3":5516,"PHASE4":5522,"NA":5535},{"trials":5511,"activeCount":94},[],{"trials":5513,"activeCount":94},[],{"trials":5515,"activeCount":94},[],{"trials":5517,"activeCount":94},[5518],{"nctId":2010,"briefTitle":2011,"status":100,"phases":5519,"primaryCompletion":2013,"completion":2013,"start":2014,"enrollment":2015,"conditions":5520,"interventions":5521},[85],[2017],[1118,1866],{"trials":5523,"activeCount":94},[5524,5528],{"nctId":1110,"briefTitle":1111,"status":100,"phases":5525,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":5526,"interventions":5527},[86],[34],[1118,1097],{"nctId":5529,"briefTitle":5530,"status":131,"phases":5531,"primaryCompletion":1918,"completion":1918,"start":5532,"enrollment":205,"conditions":5533,"interventions":5534},"NCT02117050","RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate",[86],"2014-06",[15],[1118],{"trials":5536,"activeCount":94},[5537],{"nctId":5538,"briefTitle":5539,"status":100,"phases":5540,"primaryCompletion":5541,"completion":5541,"start":5542,"enrollment":5543,"conditions":5544,"interventions":5545},"NCT01207648","Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)",[],"2011-07","2010-07",307,[15],[1118],{"intervention":5547,"totalTrials":205,"cells":5548},"Choriogonadotropin alpha",{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5550,"activeCount":94},[],{"trials":5552,"activeCount":94},[],{"trials":5554,"activeCount":94},[],{"trials":5556,"activeCount":94},[],{"trials":5558,"activeCount":94},[],{"trials":5560,"activeCount":94},[5561],{"nctId":5562,"briefTitle":5563,"status":100,"phases":5564,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":104,"conditions":5567,"interventions":5569},"NCT01152866","An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)",[],"2004-12","2003-12",[5568,2351],"Ovulation Induction",[5547]]